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1 Abbreviations 
µl microliter 
µm micrometer 
ab antibody 
Acc acceleration 
ACK buffer ammonium-chloride-potassium buffer 
ADP adenosine diphosphate 
a-Gal glycolipid alpha-galactosyl ceramide  
Akt  protein kinase B 
ALT alanine aminotransferase 
ANOVA analysis of variance 
AP1 activator protein-1 
APC antigen presenting cells 
APT antiplatelet treatment 
ASH alcoholic steatohepatitits  
Asp Aspirin 
AST Aspartate Aminotransferase 
BMI body mass index 
Ca2+ Calcium 2+ ion 
CBM  CARMA1/Bcl10/MALT1 
CD cluster of differentiation 
CD-HFD choline-deficient, high-fat diet 
cDNA complementary DNA 
Clo Clopidogrel 
ColIV  collagen IV 
COX  cyclooxygenase 
CTL cytotoxic T lymphocyte 
CTLA-4 cytotoxic T lymphocyte antigen-4  
DAG diacylglycerol 
DAMP damage-associated molecular pattern 
DNA deoxyribonucleic acid 
Dcc decceleration 
ER endoplasmic reticulum  
f.c. final concentration 
FACS flow cytometry activated cell sorting 
FasL Fas ligand  
FFA free fatty acid 
FGF21 fibroblast growth factor 21 
FOV field of view 
GPIbα glycoprotein Ib alpha 
GPVI  glycoprotein VI 
GzmA granzyme A 
GzmB granzyme B  
h hour 
2 
H&E hematoxylin-eosin 
HBSS Hank's Balanced Salt Solution 
HBV hepatitis B virus 
HCC hepatocellular carcinoma  
HCV hepatitis C virus 
HFD high fat diet 
HRP  horse-radish peroxidase 
hURI  human unconventional prefoldin RPB5 interactor 
i.p. intraperitonal 
i.v. intra venous 
ICAM intercellular adhesion molecule  
ICC intrahepatic cholangiocarcinoma 
ICOS Inducible T-cell co-stimulator 
IDO Indolamin-2,3-Dioxygenase  
IFNy interferon gamma 
IL interleukin 
IP3 inositol trisphosphate 
IPGTT intraperitonal glucose tolerance test 
irAEs immune-related adverse effects 
ITAM Immunoreceptor tyrosine-based activation motif 
Itga2b  integrin alpha-IIb 
ITIM Immunoreceptor tyrosine- based inhibitory motif 
KC Kupffer cell 
LAG-3 lymphocyte-activation gene 3  
LAT linker-of-the-activation-of-T-cells 
Lck lymphocyte cell-specific protein-tyrosine kinase 
LFA-1 Lymphocyte function-associated antigen 1 
LS low sugar 
LSEC liver sinusoidal endothelial cell 
Ly6G  lymphocyte antigen 6 complex locus G6D 
MAP kinase  mitogen-activated protein kinase 
MCD methionine-choline deficient diet 
mDC myeloid dendritic cell 
MHC major histocompatibility complex 
min minutes 
ml milliliter 
NAFLD non-alcoholic fatty liver disease  
NAS NAFLD activity score  
NASH non-alcoholic steatohepatitis 
ND normal diet 
NFAT nuclear factor of activated T cells  
NF-κB  nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
NK natural killer cells 
NKT natural killer T-cells 
o.n. overnight 
3 
OCT  optimal cutting temperature 
PAMP pathogen-associated molecular pattern 
PBS phosphate buffered saline 
PCR Polymerase chain reaction 
PD-1 programmed death receptor 1 
pDC plasmacytoid dendritic cell 
PDK1  3-phosphoinositide- dependent protein kinase 1 
PD-L1 programmed death receptor ligand 1 
PI(4,5)P2 phospholipid phosphatidylinositol 4,5 bisphosphate 
PI3 kinase  Phosphoinositide 3-kinase 
PKCθ protein kinase C θ 
PLT platelet 
Prf perforin 
PSC Primary Sclerosing Cholangitis 
Rag-1 recombination-activating gene 1 
RIPA Radioimmunoprecipitation assay 
ROS reactive oxygen species 
rpm rounds per minute 
RPMI medium Roswell Park Memorial Institute medium 
RT room temperature 
SEM standard error of the mean 
SLP-76 Src homology 2 domain–containing leukocyte phosphor-protein 
STAT signal transducer and activator of transcription 
TCR t-cell receptor 
TGF- β  transforming growth factor ß 
TIGIT T cell immunoreceptor with Ig and ITIM domain 
TIM-3 mucin-domain containing-3  
TLR Toll-like receptor 
TNF-a tumor necrosis factor alpha 
tSNE  t-distributed stochastic neighbor embedding 
VCAM vascular cell adhesion molecule  
VLA-4 very late antigen-4  
VWF von Willebrand factor 
WD western-style diet 
WD-HTF western-style diet with trans fats 
β2m β2-Microglobulin 
4 
  
5 
2 Summary 
Due to the consumption of high caloric food combined with an increased sedentary lifestyle, 
the incidence of overweight and obesity is growing rapidly in western cultures, like the USA, 
Europe and notably also in developing countries (e.g. India, China) - as a consequence of 
adaptation to the western lifestyle1–3. Thus, obesity-related pathologies like metabolic 
syndrome have become a major issue in modern medicine, and thus far therapeutic options 
are limited3–5.  
The liver - the major metabolic organ of the body - is particularly affected by constant high 
caloric food intake. Consequently, the liver undergoes dramatic changes, including the 
development of fatty liver disease, termed non-alcoholic fatty liver disease (NAFLD). In 25% 
of all NAFLD cases, progression to a more severe pathology termed non-alcoholic 
steatohepatitis (NASH) can be observed. Immune cell activation in NASH leads to liver fibrosis 
and subsequently to hepatocellular carcinoma (HCC)3,6. Today, more than 90 million people in 
the USA and 30 million people in Europe are affected by NAFLD. Although chronic viral 
infections with Hepatitis B or C are the leading etiology causing HCC, it has become clear that 
NASH is an increasingly important factor for HCC development, a notion supported by the fact 
that HCC is currently the fastest rising cancer in the USA, with a similar trend in Europe. At the 
same time, knowledge about the key mechanisms causing NASH and NASH-triggered HCC 
are scarce and therefore efficient therapies to treat this diseases are lacking3,7,8. 
The group of Professor Heikenwälder generated a mouse model of NASH and NASH-driven 
HCC in the context of a chronic metabolic syndrome6. Mice fed a long-term choline-deficient 
high fat diet (CD-HFD) develop obesity, steatosis, fibrosis, NASH and NASH-triggered HCC, 
recapitulating most of the key features found in human patients. In this model, activated CD8+ 
and NKT-cells drive NASH and HCC through cytokine-mediated crosstalk with hepatocytes. 
Remarkably, a similar T-cell activation, cytokine and immune cell pattern was found in NASH 
patients - establishing the clinical relevance of the CD-HFD mouse model. 
 
Aim 1: Deciphering TCR signaling in metabolically activated T-cells in NASH and liver 
cancer development 
In this scientific context, I investigated the role of T-cells in greater detail and T-cell receptor 
(TCR) dependent signaling in NASH development and NASH-induced HCC. By utilizing 
different dietary (high fat diet (HFD), CD-HFD and western-style diet with trans-fat (WD-HTF), 
genetic mouse models (C57Bl6, TCRβδ-/-, OT-1, Prf1-/-, Jα18-/-, CD1d-/-) and interventional 
antibody (α-CD8, α-PD-1, α-NK1.1) -based strategies in dietary mouse models, I shed new 
light on the key mechanisms of NASH pathology and its progression towards HCC.  
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The data of this PhD thesis indicates that from early time points onwards, activation of subsets 
of CD8+ T-cells correlate with NASH pathology of different severity. Further, with progression 
of NASH towards advanced stages, CD8+ T-cells of animals fed NASH-inducing diets (CD-
HFD or WD-HTF) expressed increasing amounts of early activation marker CD69 and 
activation/exhaustion marker PD-1. Also, PD-1+ CD8+ T-cells expressed different TCR variable 
β chains (TCR vβ), indicating that distinct exhausted repertoires develop over the course of 
NASH. Next, I showed that NASH pathology is dependent on a functional TCRαβ repertoire 
with intact TCRαβ effector function, but less on natural killer T-cell (NKT) cell-dependent 
mechanisms. Consistent with TCRαβ dependency in NASH development, I demonstrated a 
differential role of CD8+ T-cells depending on the progression state of NASH pathology, with a 
protective function of CD8+ T-cells in early states of NASH. However, in advanced NASH CD8+ 
T-cells drive hepatic immune-related adverse effects (irAEs), resulting in liver damage and 
tumor formation potentially involving a TNF-a-mediated mechanism. 
 
Aim 2: Platelet GPIbα is a mediator and potential interventional target for NASH and 
subsequent liver cancer 
After deciphering the role of T-cells in NASH and NASH-induced hepatocarcinogenesis, I 
investigated alternative ways to target hepatic inflammation in NASH without targeting 
potentially inflammation-driving immune cell populations directly. Thus, I investigated the key 
mechanisms of cell-immune cell interactions driving early NASH pathogenesis and identified 
platelets and platelet activation as major contributors to NASH pathology and subsequent HCC 
development. Further, I deciphered that platelets could be targeted by antiplatelet therapy 
(therapeutic Ticagrelor), thereby ameliorating NASH pathology and potentially subsequent 
hepatocarcinogenesis. I could show that platelet interaction with Kupffer cells and CD44-
hyaluronan are key mechanisms of NASH progression and that GPIbα is an interventional 
target for NASH therapy.  
 
I published these results as a co-first author in Nature Medicine in April 2019 
(https://doi.org/10.1038/s41591-019-0379-5)9. 
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3 Zusammenfassung 
Aufgrund des Konsums an hoch-kalorischen Essen kombiniert mit einem wachsendem 
bewegungsarmen Lebensstils steigt in westlichen Kulturen, wie der USA, Europa, aber auch 
in Schwellenländern, wie Indien und China, die Anzahl an Übergewicht und Fettleibigkeit1–3. 
Daher sind Krankheiten, welche mit Übergewicht in Verbindung gebracht werden, wie das 
metabolische Syndrom, eine der großen Herausforderungen der modernen Medizin, da 
therapeutische Optionen rar sind3–5.  
Die Leber, als das zentrale Organ des Metabolismus, ist von dem konstanten Überfluss an 
hoch-kalorischem Essen besonders betroffen. Unter diesen Umständen verändert sich die 
Leber dramatisch. Sie entwickelt sich zur Fettleber. Ohne übermäßigen Alkoholkonsum wird 
dieses Leberkrankheitsstadium „Nicht-alkoholische Fettleber Erkrankung“ genannt (englisch: 
non-alcoholic fatty liver disease (NAFLD)). In etwa 25% aller Fälle kommt es zu einer weiteren 
Verschlimmerung dieser Lebererkrankung, welche dann als „Nicht-alkoholische 
Steatohepatitis“ bezeichnet wird (englisch: non-alcoholic steatohepatitis (NASH)). In dieser 
NASH kommt es zur Immunzellaktivierung, welche zur Leberfibrose und schlussendlich zum 
hepatozellulären Karzinom (englisch: hepatocellular carcinoma (HCC)) führt3,6. Zum jetzigen 
Zeitpunkt sind mehr als 90 Millionen Menschen in den USA und mehr als 30 Millionen 
Menschen in Europa an NAFLD erkrankt. Das führt dazu, dass obwohl chronische virale 
Infektionen, wie Hepatitis B oder C, die führenden Ätiologien der Hepatokarzinogenese sind, 
Hepatokarzinogenese als Resultat einer zugrundeliegenden NASH sich über den Zeitraum der 
nächsten Jahre zu einem ernstzunehmenden Faktor entwickeln wird. Das wird zum Beispiel 
unterstützt, dass HCC heutzutage der Krebs ist, dessen Häufigkeit am rasantesten in der USA 
und Europa wächst. Gleichzeitig ist aber der heutige Wissenschaftsstand begrenzt in Bezug 
auf das Verständnis der Mechanismen der NASH und der NASH induzierten HCC Entstehung. 
Deshalb fehlen effiziente therapeutische Maßnahmen3,7,8. 
Das Labor von Professor Heikenwälder hat ein präklinisches Mausmodell entwickelt mit 
metabolischen Syndrom, NASH und NASH induzierte Hepatokarzinogenese6. In diesem 
Model werden Mäuse über einen langen Zeitraum mit Choline defizienter Hoch-Fett Diät (CD-
HFD) gefüttert, was zu Übergewicht, Steatose, Fibrose und schlussendlich zu einer NASH 
Pathologie mit resultierender Hepatokarzinogenese führt. Dieses Model rekapituliert somit die 
wichtigsten Merkmale humaner NASH. In diesem CD-HFD Maus Model wird NASH durch eine 
CD8+ und NKT-Zellen Zytokin-vermittelten Interaktion mit den Hepatozyten induziert. Ein 
besonderes Augenmerk ist auch darauf zu richten, dass in NASH Patienten ein ähnliches T-
Zell Aktivierungsprofil mit analogen Zytokin-vermittelten Mechanismen gefunden wird, was die 
klinische Relevanz unseres Mausmodels unterstreicht. 
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Ziel 1: Entschlüsselung des TCR Signalings in metabolisch aktivierten T-Zellen in NASH 
und Leberkrebs Entstehung  
In diesem wissenschaftlichen Kontext wurde in dieser PhD Thesis die Rolle von T-Zellen 
detaillierter als zuvor, sowie T-Zell Rezeptor (englisch: T-cell receptor (TCR)) abhängigen 
Mechanismen untersucht, welche zu der NASH Entstehung und der NASH induzierten 
Hepatokarzinogenese wichtig sind. Dazu wurden verschiedene Diäten (Hoch-Fett Diät (HFD), 
CD-HFD, Western-Stil Diät mit Trans-Fetten (englisch: western-style diet with trans-fat (WD-
HTF))), genetische Maus Modelle (C57Bl6, TCRβδ-/-, OT-1, Prf1-/-, Jα18-/-, CD1d-/-) und 
Antikörper basierte Strategien (α-CD8, α-PD-1, α-NK1.1) in den Diät-Maus Modellen 
verwendet. Dies ermöglichte es, neues Licht auf Mechanismen der NASH Pathologie 
Entstehung und deren Progression zum hepatozellulären Karzinom zu entschlüsseln. 
Die gewonnenen Daten deuten darauf hin, dass nur in NASH induzierenden Diäten, wie der 
CD-HFD oder der WD-HTF, von einem frühen Zeitpunkt an CD8+ T-Zellen aktiviert werden 
und diese daraufhin mehr frühe Aktivierungsmarker CD69 und den Aktivierungs-
/Erschöpfungsmarker PD-1 über den Verlauf der NASH Pathologie exprimieren. Weiter deuten 
meine Daten darauf hin, dass es zu einer differenziellen TCR variablen Ketten β (TCR vβ) 
Expressionen in PD-1+ CD8+ T-Zellen kommt, was auf verschiedene erschöpfte TCR 
Repertoires im Verlauf der NASH schließen lässt. Auch konnte ich zeigen, dass die 
Entstehung und Progression der NASH Pathologie nur mit einem natürlichen TCRαβ 
Repertoires mit intakter TCRαβ Effektor Funktion möglich ist. Mechanismen, die mit 
Natürlichen Killer T-Zellen (NKT) in Verbindung gebracht werden, scheinen eine eher 
untergeordnete Rolle in unseren verwendeten NASH Modellen zu spielen. Zusätzlich zu der 
Abhängigkeit von einem natürlichen und intakten TCRαβ Repertoire für die NASH Entstehung 
konnte ich zeigen, dass CD8+ T-Zellen je nach Progressionsstand der NASH Pathologie eine 
unterschiedliche Rolle haben. Zum Beispiel in frühen Stadien der NASH scheinen CD8+ T-
Zellen einen eher protektiven Charakter zu haben. Wohingegen in fortgeschrittenen Stadien 
der NASH CD8+ T-Zellen für immun-abhängigen schädlichen Effekte (englisch: immune-
related adverse effects (irAEs)) verantwortlich sind, welche zu Leberschädigung, stärkerem 
Leberschaden und Tumor Entstehung über einen möglicherweise TNF-a vermittelten 
Mechanismus führen. 
 
Ziel 2: Platelet GPIbα ist ein Mediator und potentielles Ziel für eine medikamentöse 
Therapie in NASH und Leberkrebs 
Auf der Suche, um den Kreislauf der hepatischen chronischen Entzündung in NASH 
durchbrechen zu können, habe ich bei der Erstellung dieser Thesis Schlüssel-Mechanismen 
untersucht, die verantwortlich für die NASH Pathogenese sind. Ich habe Zell-Immunzellen 
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Interaktion analysiert. Dabei habe ich Blutplättchen (Platelets) und Platelet Aktivierung als 
verantwortliche Mechanismen identifiziert, welche NASH treiben und somit Lebertumor 
Entstehung möglich machen. Platelets konnten mit anti-Platelet Therapie (therapeutischen 
Einsatz von Ticagrelor) gezielt beeinflusst werden und somit NASH Pathologie Progression 
verhindert oder NASH Pathologie verbessert werden. Weiter konnte ich zeigen, dass Platelet 
Interaktion mit Kupfferzellen und CD44-Hyaluron wichtige Mechanismen des Fortschreitens 
von NASH sind. Weiter, konnte ich GPIbα als ein therapeutisches Zielmolekül für die NASH 
Therapie identifizieren. 
 
Diese Ergebnisse konnte ich als ein Erstautor in Nature Medicine im April 2019 publizieren 
(https://doi.org/10.1038/s41591-019-0379-5)9. 
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4 Introduction 
 
4.1 General Introduction 
4.1.1 The liver 
The liver is the central metabolic organ of the mammalian system, which links the absorbance 
of external substances through the gastrointestinal tract to the portal vein or lymph tract. 
Consequently, the liver serves a barrier and filter function. Further, the liver breaks down 
digestible ingredients of ingested food to useable micro- and macronutrients. Next, the liver 
enriches the circulating blood with nutrients for peripheral organs, as well as detoxifying 
potential harmful substances10. The liver therefore serves as a crucial homeostatic organ 
balancing peaks of nutritional overload and subsequent energy excess after eating against 
times of fasting to keep a constant level of metabolites like glucose and fats bound to the 
different lipoproteins in the circulating blood10. Also, the liver is a self-regenerative organ, able 
to regenerate completely by compensatory growth mechanism even after loss of up to 75% of 
its original mass10,11. 
The liver`s functional structure is composed of a unique fenestrated architecture, which 
increases the interaction surface with surrounding fluids for maximal exchange rates of 
metabolites, proteins and fats10. The liver`s main cell type is the hepatocyte, which is capable 
of storing, synthesizing and producing the molecules needed for a functional mammalian 
system, like cholesterol, bile salts, phospholipids, proteins and stabilizing carbohydrates 
levels10. The second hepatic cell type is the cholangiocytes, which in addition to the 
hepatocytes, produce some of the bile acids needed for food resorption. Further, there are a 
plethora of cells of the endothelium, the liver sinusoidal endothelial cells (LSECs) and 
leukocytes, both resident as well as patrolling cells (e.g. Kupffer cells (KC), yδ T-cells, natural 
killer (NK), natural killer T (NKT) cells and myeloid lineage cells like dendritic cells). The liver 
has traditionally been considered to have a gatekeeper function, digesting food, detoxifying 
potential harmful substances from the periphery and handling danger signals derived from the 
intestine, like bacterial components. Therefore, the liver has a remarkably anti-inflammatory 
microenvironment, allowing the liver to train and form the immunological responses and thus 
the immunological landscape. In conclusion, the liver has a central role as a metabolic organ, 
as well as in shaping the hormonal and immunological landscape10. 
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4.1.2 Hepatocellular carcinoma 
Although remarkable progress in terms of survival, response and treatment options for nearly 
every known cancer type has been achieved in the last decade, a few entities are opposing 
this trend of progress in anti-cancer diagnosis and successful therapies. One of these entities 
is hepatocellular carcinoma, which is the primary cancer type of the liver3. This leads to high 
mortality rates, which are still increasing, despite modern medical advances12. Depending on 
the stage and thereby the severity of liver cancer, this results in a low median 5 year survival 
rate between 4-17.2%3,4,13. Primary liver cancer, the 5th most common cancer type detected, 
can be grouped into multiple entities. A relatively small proportion of liver cancer arises from 
non-epithelial tumors and pediatric hepatoblastoma, 10-15% result from cholangiocarcinoma 
(Figure 1a), but the main burden, accounting for 80-90% of all liver cancer, comes from 
hepatocellular carcinoma (HCC) (Figure 1b)3. A ratio of 3:1 of primary liver cancer in 
males/females indicate that men are especially prone to developing liver tumors14,15. 
While the underlying mechanisms for HCC induction is strongly dependent on geographical 
region in worldwide incidences, in 90% of HCCs the underlying mechanisms for induction is a 
chronic inflammation of various origins, leading to different degrees of fibrosis and cirrhosis3. 
Viral infections are still the leading cause of chronic liver inflammation, but due to lifestyle 
changes, alcohol and dietary-induced liver inflammation are gaining importance as HCC 
etiologies in areas of the world traditionally having low HCC rates (Figure 1c). However, 
chronic inflammation in regenerative organs like the liver lead to a hepatic environment of 
constant cell death and increased compensatory proliferation through increased activation of 
liver progenitor cells and non-parenchymal cells3. This chronic cycle of death and regeneration 
is termed “chronic necroinflammation”3. The high turnover of cells in a chronic 
necroinflammatory environment results in DNA damage, epigenetic modifications and an 
overall genetic instability, paired with increased senescence of cells and intracellular stress, 
leading overall to the fibrosis and scarring of liver tissue, which is the soil of tumorigenesis 
(Figure 1c)3. 
 
4.1.3 Underlying aspects of chronic inflammation for hepatocellular carcinoma 
development 
The current understanding of liver cancer development suggests that chronic inflammation 
leads to constant stress on hepatocytes and liver-associated cells, resulting in chromosomal 
aberrations, cell death, necroinflammation, an inflammatory cytokine milieu and compensatory 
proliferation of hepatocytes and progenitor cells, as well as immune cell activation3,16. Further, 
this inflammatory environment leads to activation of hepatic stellate cells, inducing enhanced 
production of extracellular matrix mostly consisting of collagen, resulting in scarring of the liver 
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and increased liver stiffness. Scarring of liver tissue leads to cirrhosis, and combined with an 
impaired immune surveillance, results in a pro-oncogenic hepatic environment, which induces 
aberrant cells, lesions and liver cancer formation17. 
 
 
Figure 1: Chronic inflammatory stimuli drive necroinflammation and subsequent hepatocarcinogenesis 
(adapted from Ringelhan et al.3) 
(a) Examples of resected ICC and (b) HCC in collaboration with Achim Weber. (c) Chronic inflammatory stimuli of 
various origin (virus, metabolic excess, alcohol abuse) deregulate the liver immune network, induce cell death and 
compensatory proliferation. This necroinflammation drives genetic instability and fibrosis leading to 
hepatocarcinogenesis. Also intrahepatic cholangiocarcinoma (ICC) develops in the background of chronic 
inflammatory stimuli (primary sclerosing cholangitis (PSC) and liver flukes).  
 
The multitude of variables influencing liver cancer formation is also represented by the 
complexity and different mutational backgrounds of liver cancer found in patients, making 
therapeutic approaches difficult and patient-specific3.  
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The liver cancer`s underlying chronic inflammation can arise via different etiologies, with viral 
infections of HBV and HCV currently being the most common. However, with the epidemic rise 
of metabolic syndrome and obesity all over the world, metabolically-induced liver cancer is 
continually rising18–20. 
Despite increasing alcohol abuse leading to alcoholic liver disease and alcoholic 
steatohepatitis (ASH), an increasing contributor to liver inflammation is correlated to over 
nutrition combined with a sedentary lifestyle with or without extensive alcohol abuse (less than 
two alcoholic beverages per day)21,22. This liver pathology, termed non-alcoholic fatty liver 
disease (NAFLD) and its more severe form non-alcoholic steatohepatitis (NASH) are the most 
prevalent causes of dietary-induced HCC23. 
Further, epidemiologic studies show that in adipose patients with a body mass index (BMI)>30 
kg/m2 and a high caloric intake combined with a sedentary lifestyle the cancer incidence 
massively increases by up to six-fold20,24. 
 
4.1.4 Dietary steatohepatitis as a driver of hepatic carcinogenesis 
Thus, I wanted to focus on dietary-induced pathologies and HCC, due to the exorbitantly rising 
burdens of overweight, obesity and metabolic-related disease like e.g. Type II diabetes in 
western cultures like the USA and Europe, but also in developing countries in the past 30 
years1–3,25. 
NAFLD is characterized by a reversible increase in liver fat deposition in hepatocytes, resulting 
in micro- and macro-steatosis, systemic increase of fatty acids (e.g. triglycerides, cholesteric 
derivatives), insulin resistance and therefore development of metabolic syndrome on the 
background of non-significant alcohol intake (Figure 2a)21,22,25. Although reversible, the 
prevalence of NAFLD is high, affecting people on an epidemic scale. For example, in the 
United States approximately 20-30% of the adult population are diagnosed positive for NAFLD 
and an alarmingly incidence of 10% of children positive for NAFLD, as well25,26. Further, NAFLD 
is on a steady rise with 15% of the US population affected in 2005 to 25% affected after only 
5 more years, in 2010 (Figure 2b)25. Similar rates of 20-30% of NAFLD prevalence were 
reported on a global scale, affecting an epidemic scale of more than 1 billion people25,27,28. 
Depending on the population (e.g. ethnicity, gender) and region of individual studies, 
progression to the more severe pathology, NASH, can be observed in 15-26% of all NAFLD 
cases. For example, in a US cohort between 3-4% of the adult population was affected, which 
nearly doubled from 2005 to 2010 (Figure 2b) 25,27. What exactly drives NAFLD to NASH 
progression is not understood, but there are indications that there are multiple hits or drivers 
of pathogenesis. Hits including further metabolic reprogramming, lipid toxicity and increasing 
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endoplasmic reticulum (ER) stress as a result of the underlying NAFLD and metabolic 
syndrome. However, one of the defining features of NASH is an immune cell-meditated mostly 
liver-associated inflammatory component (“sterile inflammation”) fueling the previously 
described chronic necroinflammation and subsequent fibrosis, which is one of the defining 
mechanisms of HCC development3,29. 
Chronic necroinflammation, including the frequently induced fibrosis, leads to the activation of 
damage-associated molecular patterns (DAMPs), pathogen-associated molecular patterns 
(PAMPs), Toll-like receptors (TLRs), together with increased levels of reactive oxygen species 
(ROS), toxic metabolites (e.g. high cholesterol and free fatty acids levels) and increasing 
concentrations of cytotoxic cytokines (e.g. TNF-a). This inflamed environment affects not only 
hepatocytes and stellate cells, but immune cells, both innate, e.g. dendritic and Kupffer cells, 
and adaptive immune cells like cluster of differentiation (CD) 4+ or CD8+ T-cells, in particular 
(Figure 3)6,22,26,29,30. The exact sequence of progression as a result of the chronic 
necroinflammation from NASH to HCC is not fully understood. On an immunological level, 
selective loss of CD4+ T-cells by cytotoxic fatty acids induces less macrophage-mediated 
clearance of senescent hepatocytes, as well as a potential tolerance break due to decreased 
numbers of regulatory T-cells31,32. In addition, CD8+ subsets drive liver damage in established 
NASH in a CD-HFD-based mouse model (Figure 3)6,33. Further, CD8+ T-cells express 
programmed death receptor 1 (PD-1+) in HFD-induced NAFLD, indicating an exhausted T-cell 
phenotype34. Further, IgA+ B-cell-mediated suppression of anti-tumoral CD8+ subsets together 
with a change of NKT cell polarization and disruption of the immune-tolerant liver environment 
by M1/M2 shifting of myeloid cells were found to correlate with tumor promotion (Figure 3)3,35–
37. On a molecular level, there is an intense “cross-talk” between immune cells and hepatocytes 
responsible for HCC induction/development. In general, dysregulation or activation of TLR 
through DAMPs and PAMPs, canonical and non-canonical NF-κB signaling lead to tumor 
induction, with mediators including molecules such as TNF-a, lymphotoxin β, interferon gamma 
(IFNy), ROS, IL-1β, IL-6, , IL-10, TGF-β and alarmins including IL-333,13,20,21. 
 
In summary, a high global prevalence of underlying inflammatory conditions, lack of 
therapeutic strategies and predictions of a global increase in HCC rates, makes HCC one of 
the most dangerous cancer entities besides hormonal carcinogenesis. As a result, a diagnosed 
HCC, regardless of the underlying cause, is for the individual patient essentially a death 
sentence. 
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4.1.5 Mouse models of non-alcoholic steatohepatitis 
Due to the complexity of non-alcoholic steatohepatitis-induced hepatocarcinogenesis, 
modelling key mechanisms and facets of the underlying disease, NAFLD and NASH, in animal 
models is challenging38,39. Aspects of an appropriate model must include systemic obesity, 
insulin resistance, hepatic steatosis and steatohepatitis, as well as forms of fibrosis that lead 
subsequently to HCC development38–40. 
 
 
Figure 2: Hepatocarcinogenesis in the background of a non-alcoholic fatty liver disease (adapted from 
Dannenberg and Berger41 and Anstee et al.42) 
(a) Sedentary life-style and nutrient excess lead to obesity, insulin resistance and free fatty acids (FFA) influx to the 
liver, inducing simple steatosis. Simple steatosis progresses to non-alcoholic steatohepatitis (NASH), which 
progresses to fibrosis and cirrhosis in the context of necroinflammation. Liver cancer can develop not only from 
fibrotic/cirrhotic, but also from steatotic or NASH livers lacking fibrosis. (b) Overview of incidence rates for 
progression from normal liver, to simple steatosis, NASH, fibrosis, cirrhosis and liver cancer. 
 
In principle, three different experimental approaches to model NAFLD in different severity 
states with varying probabilities of progression to HCC can be done (Table 1, adapted from 
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Anstee et al.42). The first approach employs the use of chemical carcinogens (e.g. carbon 
tetrachloride or diethylnitrosamine with or without high-fat diets)43,44. The second approach 
uses genetically altered mouse models (e.g. leptin-deficient ob/ob mouse strains or 
unconventional prefoldin RPB5 interactor (URI) with or without high-fat diets)45,46. 
 
 
Figure 3: Immune cell mediated contribution driving or counteracting HCC development with 
therapeutically approaches (adapted from Ringelhan et al.3) 
Network of immune cell driving or inhibiting development of HCC by direct or cytokine mediated mechanisms. In 
particular chronic stress drive malignant transformation of hepatocytes by cytotoxic or pro-inflammatory polarized 
CD4+ and CD8+ T-cells (red arrows). Anti-inflammatory mechanisms by B-cells, regulatory T-cells and M2 polarized 
myeloid cells inhibit effect anti-tumor surveillance in concert with increased IL-10 and TGF-β levels, as well as T-
cell exhaustion. In grey boxes are potential clinical approaches for therapy by blocking exhaustion signals on T-
cells, increase cytotoxic cells by adoptive transfer or vaccination, or physical based tumor destruction methods like 
microwave or transarterial chemoembolization (TACE). TAA, tumor-associated antigen; RFA, radiofrequency 
ablation; CAR, chimeric antigen receptor; CIK cells, chemokine-induced killer cells; Breg cells, regulatory B cells; 
TME, tumor microenvironment; GITRL, ligand for GITR3. 
 
The third approach uses dietary mouse models that involve feeding different styles of diets 
either to wild type or to genetically modified mice (e.g. methionine/choline-deficient [MCD] 
feeding; liver specific c-myc transgenic mice fed a MCD; high-fat diet [HFD] feeding; 
overexpression of urokinase plasminogen activator leading to constant endoplasmic reticulum 
stress mostly in hepatocytes (MUP-uPA transgenic) mice fed a HFD; long-term “western-style” 
diets, which include increased fructose and cholesterol levels or choline-deficient high-fat 
diets) (Table 1, adapted from Anstee et al.42)6,31,37,47. 
Wild type mouse models, which rely on feeding of specific diets alone, are an ideal method of 
modelling the initiation, establishment and progression of NAFLD, NASH and HCC, as they do 
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not rely on genetic alterations, which are not observed in human disease. Further, the rather 
slow pace of disease development by long-term diet feeding allow for in depth investigation at 
stages of earliest steps of disease initiation, progression to NAFLD, early or advanced NASH9. 
 
Table 1: Overview of animal models of NAFLD, NASH and HCC development (adapted from Anstee et al.42) 
Model NAFLD NASH Metabolic 
Syndrome 
HCC Comments 
WD/CCL448  + + + + Steatosis: + 
Fibrosis: ++ 
Weight loss  
HCC development 
DEN/HFD49 + + + + Steatosis: + 
Fibrosis: - 
Obesity 
HCC development 
Ob/ob39 + - + - no spontaneous NASH or HCC 
URI-IL17 / HFD/ 
CD-HFD46 
+ + + + Steatosis: + 
Fibrosis: +/- 
Obesity 
HCC development 
Methionine-choline 
deficient diet 
[MCD]50 
+ + Weight loss, 
cachexia  
- steatosis, fibrosis and cachexia, but 
HCC development is infrequent 
MYC-ON 
mice/MCD31  
+ +  - + Steatosis: + 
Fibrosis: + 
HCC development 
High-fat diet 
[HFD]50 
+ - + + / - steatosis and obesity but not 
fibrosis 
HCC incidence is very low 
MUP-uPA 
mice/HFD51 
+ + + + Steatosis: + 
Fibrosis: + 
Obesity 
HCC development 
High-fat/ cholesterol 
high fructose diet 
[WD]47 
+ + + + Steatosis: + 
Fibrosis: ++ 
Obesity 
HCC development 
Choline deficient 
High-fat diet 
[CD-HFD]6  
+ + + + steatosis, fibrosis, obesity, 
metabolic syndrome  
HCC development 
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Thus, models using choline-deficient high fat diet feeding (CD-HFD) were utilized within the 
framework of the current PhD thesis due to its representation of NASH phenotype observed in 
the clinics and its ability to reproduce the whole spectrum of disease initiation leading to NAFLD 
and NASH ending in dietary induced hepatocarcinogenesis without genetic drivers. This CD-
HFD model induces systemic obesity, metabolic syndrome, liver steatosis and liver 
inflammation after 6 months of diet feeding and subsequent liver tumor development in 25% 
of all CD-HFD fed mice after 12 months (Figure 4, adapted from Wolf et al.6). In particular, a 
cytokine-mediated (e.g. LIGHT) cross-talk between NKT, adaptive immune cells of the CD8 
lineage and hepatocytes cause liver steatosis, inflammation and subsequent HCC by 
hepatocellular LTβR and canonical NF-κB signaling NASH to tumor transition (Figure 4, 
adapted from Wolf et al.6). 
 
 
Figure 4: Mechanistic underpinnings of the CD-HFD mouse model (adapted from Wolf et al.6) 
Chronic CD-HFD feeding induces dyslipidemia, choline deficiency and ROS formation together with NKT cells and 
LIGHT driving the transformation of healthy hepatocytes to steatotic hepatocytes. Steatotic hepatocytes change 
and get metabolically reprogrammed by chronic exposure to inflammation mediated by activated CD8+ T-cells and 
NKT cells and nutrient excess of the CD-HFD. Thus, necroinflammation with chronic cell death and compensatory 
proliferation induces genetic instability, which transforms hepatocytes in NF-κB mediated processes to drive 
hepatocarcinogenesis. 
 
4.2 Understanding drivers of chronic liver inflammation – T-cells 
4.2.1 T-cells 
Due to the known role played by T-cells in dietary liver inflammation, a more thorough analysis 
of how they mediate cytotoxicity should be performed. In general, the T-cell lineage can be 
subdivided into two major classes of T-cells, first invariant T-cells including natural killer T-cells 
and T-cell receptor (TCR) γδ T-cells and second, classical TCRαβ T-cells, which can be 
subdivided into CD4+ T-cells and CD8+ T-cells52.  
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Depending on the microenvironment, T-cells have different roles. Generally speaking, invariant 
T-cells are the patrolling, organ-specific cells, the first responders to tissue damage and 
detection of foreign proteins from e.g. bacteria53. These invariant T-cells are therefore 
considered to be innate-like T-cells and have a bridging role between the innate and adaptive 
immune system54. 
CD4+ T-cells are the so-called helper T-cells, whose function is to mediate cellular immunity 
(TH1 polarization) by e.g. granzyme A/B (GzmA/B) or indirectly by interaction with monocytes 
to clear senescent cells3. Further, TH2-polarized CD4+ T-cells influence immune reactions 
either in a promoting manner (e.g. supporting humoral B-cell-mediated immune responses 
through IL-4), or a dampening manner (e.g. anti-inflammatory, regulating role of T regulatory 
cells through IL-10)52. An additional subset of CD4+ T-cells are the TH17 cells, which mainly 
produce IL-17 and are important in chronic inflammation and autoimmunity. 
In contrast, CD8+ T-cells, although capable of fulfilling regulatory and anti-inflammatory 
functions in certain contexts (e.g. intestinal barrier function), are more efficient and prone to 
being cytotoxic T lymphocytes (CTLs). Classical CD8+ T-cells are considered efficient killer 
cells, patrolling the body constantly checking cells for foreign peptide structures presented in 
a major histocompatibility complex (MHC) I TCR-interacting fashion52. Upon detection of 
foreign antigens (e.g. on virus-infected cells), CTLs inject granzymes through perforin into the 
target cells. In parallel, cytotoxic cytokines like IFNy or TNF-a get released, inducing a strong 
local inflammatory reaction. 
 
4.2.2 TCR signaling 
The classical αβ TCR is a cell membrane-anchored protein complex orientated toward the 
outside of the cell, building a complex with the CD3 chains, which point to the inside. Through 
this difference in orientation, signal transduction from extracellular signals to the inside is 
achieved. Upon TCR stimulation by interaction of the specific TCR with its mutual antigen 
presented by MHC molecules, a multi-layered and feedback-controlled signal cascade starts, 
leading either to T-cell activation or, when co-stimulation is insufficient to T-cell anergy 
induction, a state in which T-cells become unresponsive to additional TCR stimuli52,55,56. 
For signal transduction, CD3 chains possess different amounts of biochemically exposed 
tyrosines for immunoreceptor tyrosine-based activation motifs (ITAMs), which upon 
phosphorylation by e.g. lymphocyte cell-specific protein tyrosine kinase (Lck) recruit different 
kinases (e.g. ZAP-70). ZAP-70 recruitment leads to a phosphorylation cascade of linker-of-
the-activation-of-T-cells (LAT) and cytosolic adapter protein Src homology 2 domain–
containing leukocyte phosphor-protein of 76 kDa (SLP-76), which unleash MAP kinase 
pathways upon phosphorylation for effective TCR signaling amplification and transduction. 
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Further, Lck leads to PI3 kinase activity combined with phospholipase C, which regulates 
intracellular Ca2+ levels by the PI(4,5)P2 – IP3 – DAG signaling pathway (phospholipid 
phosphatidylinositol 4,5 bisphosphate - inositol trisphosphate – diacylglycerol). Downstream of 
PI3K, other kinases (e.g. PKCθ) amplify on the one hand further TCR signals and on the other 
hand induce the formation of the CBM (CARMA1/Bcl10/MALT1) complex. Depending on the 
activated pathway, different transcription factors get used (e.g. nuclear factor of activated T 
cells (NFAT), activator protein-1 (AP1), NF-κB, signal transducer and activator of transcriptions 
(STATs)). Upon their simultaneous activation and interaction, T-cells get activated (e.g. NFAT 
activated together with AP-1) and produce IL-2 or T-cells become anergic (e.g. NFAT activated 
without AP-1)52,55. 
Further, a process called inside-out signaling leads upon TCR stimulation to actin cytoskeletal 
changes and enhanced integrin binding (e.g. lymphocyte function–associated antigen-1 (LFA-
1), very late antigen-4 (VLA-4) and their cognate ligands intercellular adhesion molecule 
(ICAM) and vascular cell adhesion molecule (VCAM))55. 
However, all these changes upon TCR stimulation and activation are controlled on multiple 
levels in a context-specific manner, e.g. by specific phosphatases like CD45, SH2 domain–
containing protein- tyrosine phosphatase (SHP1, SHP2 and PP2A) recruited to phosphorylated 
ITIMs (immunoreceptor tyrosine- based inhibitory motifs e.g. in T cell immunoreceptor with Ig 
and ITIM domains, short TIGIT), or HPK1 binding to SLP7655. An example of this dual 
regulation is CD45, which can either dephosphorylate Lck`s inhibitory domains and allowing 
Lck activation, or by dephosphorylating Lck`s active sites and limiting its signaling potential55. 
In conclusion, there are multiple pathways and interaction sites translating TCR stimuli into T-
cell phenotypic changes, thus allowing them to distinguish between specific, acute and chronic, 
as well as weak and strong TCR stimuli. 
 
4.2.3 T-cell exhaustion 
For an effective T-cell response, a TCR stimulus alone is not sufficient, but induces T-cell 
anergy. Therefore, simultaneous co-stimulatory signals parallel to TCR stimuli are important 
(Figure 5). One of the prominent examples is the receptor interaction of CD28 on T-cells and 
CD80 or CD86 on antigen presenting cells (APCs), inducing T-cell intracellular PI3K signaling, 
leading to PDK1 (3-phosphoinositide- dependent protein kinase 1), Akt and NF-κB activation 
through the CBM complex. Other co-stimulatory receptors are CD2, CD5, CD137, OX40, 
Inducible T-cell co-stimulator (ICOS) and the previously described LFA-1. Upon effective T-
cell activation the activation chemokine IL-2, the survival factor Bcl-xl and proteins involved in 
increasing metabolic capacities (e.g. Glut1 increasing glucose uptake and glycolysis) are 
increased55–58. 
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Prolonged and chronic TCR activation leads to an exhausted T-cell phenotype, characterized 
by first a decreased response to antigen stimuli by downregulation of CD3 or a decreased 
response to survival signals like IL7 or IL15 by reduced expression of CD122, the β-chain of 
the IL-2 and IL-15 receptor, and CD127, which is the α-chain of the IL-7 receptor. Second, 
poor T-cell effector function (e.g. decreased production of IL-2, IFNy, and TNF-a; decreased 
cytolytic capacity by Fas ligand or the GzmB/perforin axis) is observed, and third, expression 
of inhibitory receptors like lymphocyte-activation gene 3 (LAG-3), mucin-domain containing-3 
(TIM-3), cytotoxic T lymphocyte antigen-4 (CTLA-4) and PD-1 are increased (Figure 5)55–58. 
For example, LAG-3 interaction with MHC II affects cell cycle progression; CTLA-4 affects co-
stimulation of T-cells by competing with CD28 as a high affinity binding partner to CD80/CD86, 
and trans-endocytosis of CD80/CD86; PD-1/PD-L1 interaction recruits T-cell internal 
phosphatases, thereby limiting TCR dependent signaling. Further, chemokines like IL-10 or 
TGF-β, activation of amino acids (e.g. tryptophan), depleting enzymes like indolamin-2,3-
dioxygenase (IDO) or immunoregulatory cells (e.g. Tregs or M2 polarized myeloid cells) 
contribute to an exhausted phenotype or induce further Treg formation55–58. Therefore, a non-
effective clearance of a TCR stimulus and prolonged T-cell activation, like in HBV infections or 
chronic hepatitis, leads to T-cell exhaustion and eventually to chronic inflammatory conditions. 
 
4.3 Platelets –mediators of chronic liver inflammation 
In order to understand early mediators of chronic dietary-induced liver inflammation in greater 
detail and to potentially therapeutically intervene with these inflammatory mechanisms, 
previous work in the group of Mathias Heikenwälder investigated the role of platelets59. It has 
become evident that platelets play a more prominent role in mediating inflammatory processes 
than initially appreciated. Reports of other disease entities like thrombosis, obesity, 
atherosclerosis, metastasis, cancer and stroke suggested that platelets could potentially 
mediated adverse effects in a chronic liver inflammation9,60–63. 
In the background of virus-induced liver inflammation, platelets were identified as a crucial 
factor mediating cytotoxic T-cell responses64–66. Further, platelets contributed to hepatitis B-
mediated HCC development, aggressivity and subsequent survival of infected mice. Thus, 
antiplatelet therapy by Aspirin-Clopidogrel was beneficial in this mouse model of hepatitis B by 
reducing hepatic T-cell migration and accumulation, inducing prolonged survival of infected 
mice67.  
Therefore, a growing body of literature implicates platelets as key mediators of damage and 
inflammation, rather than as a bystander effector cell contributing to inflammation. 
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4.3.1 Platelet biology 
Platelets derive from the megakaryocytes in the bone marrow by fragmentation and have a 
relatively short life time of approximately 7 days60,68. Platelets lack a nucleus but have 
characteristics of whole cells. Traditionally, platelets are involved in wound closing, thus blood 
clotting, wound healing, angiogenesis, but also promoting local leukocyte recruitment by 
changing the local cytokine/chemokine environment9,59,60. 
 
 
Figure 5: Important factors of co-stimulation or inhibition of TCR signaling (adapted from Chen et al.58) 
Intracellular signaling network downstream of TCR and co-stimulatory (ICOS and CD28) or co-inhibitory (PD-1 and 
CTLA-4) receptors on T-cells indicating interaction and cross-talk determining T-cell reaction (activation, inhibition 
or anergy/hyporesponsiveness) in a context and TCR stimulus dependent manner. 
 
Platelets have different surface receptors mediating signals upon different interactions with the 
specific ligands triggering specific actions (Figure 6)69. Depending on the trigger, platelets 
have a repertoire of reactions. This includes, for example, influencing local blood flow 
parameters by platelet activation and subsequent aggregation, platelet-mediated cell 
apoptosis by Fas/FasL interaction, limited transcriptional activity of megakaryocyte-derived 
RNA, and platelet cargo release9,60. Cargo release of the platelet granules is a particularly 
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powerful mediator of the local cytokine/chemokine environment. For example, platelets release 
cytokines like immune cell-interacting TGF-β and blood flow-modulating serotonin -  not only 
in a direct manner, but also by guiding inflammatory cells “laying” paths of exosomes59,60. 
Under non-pathological conditions these processes execute mainly local defense mechanisms 
during injury and angiogenesis; however, chronic inflammatory situations reverse these 
mechanisms and promote chronic inflammation59,60,66,67. 
However, similar to van-der-Waals forces in fatty acid binding interaction or the working 
behaviour of ants, a lot of small interactions can have a large systemic effect. Therefore, one 
should not underestimate the impact of local platelet activation/aggregation and cargo release, 
because platelet abundance in healthy individuals of 1.5-3.0E11 platelets/L is increased to 
pathological levels greater than 4E11 platelets/L in diseased patients of different entities59,60. 
 
4.3.2 Antiplatelet treatments  
Different antiplatelet treatments are in clinical use modifying platelet functions in a specific 
manner (Figure 6)69. Antiplatelet treatments are in general considered safe, for example 
prolonged low-dose Aspirin (Asp) treatment, which inhibits irreversible cyclooxygenase (COX)-
1 and thereby inhibiting platelet function lifelong, are commonly used for treatment of patients 
with risk for cardiovascular disease or atherosclerosis69,70. The limitation of Aspirin as a relative 
weak antiplatelet drug can be overcome when combined with additional antiplatelet drugs, like 
Clopidogrel (Clo) 69,71. This is called dual antiplatelet therapy. Clopidogrel inhibits irreversible 
the P2Y12 receptor on platelets and thereby the adenosine diphosphate (ADP)-induced platelet 
aggregation, which is a consequence of ADP release of activated platelets at sides of injury, 
like artherosclerotic plaques (Figure 6)69,71. To circumvent the irreversibility of platelet function 
inhibition by either Asp or Clo or combined Asp-Clo, reversible platelet function inhibitors like 
Ticagrelor were developed72. Similar to Clo, Ticagrelor inhibits the P2Y12 receptor on platelets 
and thereby the adenosine diphosphate (ADP)-induced platelet aggregation, but in a reversible 
manner (Figure 6)69,72. Other prominent P2Y12 receptor inhibitors are Prasugrel, which inhibits 
platelet function irreversible but in a more rapid and consistent way compared to Clo; or 
Cangrelor, which inhibits platelet function reversible, but in contrast to Ticagrelor Cangrelor 
has the disadvantage of intravenous administration for long-term treatments69,73,74. Next, 
Abciximab, Eptifibatide, or Tirofiban are FDA approved antiplatelet treatments targeting αIIbβ3 
and thereby platelet aggregation, but also have the disadvantage of intravenous administration 
(Figure 6)69.  
In summary, antiplatelet treatments have minimal risks besides prolonged bleeding times, are 
relatively cheap and are therefore administered on a regular basis for different pathologies 
increasing clinical outcome for patients. 
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Figure 6: Platelet receptors/ligand interaction and potential interventional antiplatelet treatments (adapted 
from Michelson69) 
Receptors and respective ligands on platelet surface. Receptors playing an important role in binding to collagen are 
platelet surface glycoprotein VI (GPVI), integrin α2β1, as well as von Willebrand factor (VWF) binding to platelet 
surface glycoprotein 1b (GP1b)-IX-V complex. Further, thrombin is a potent activator of platelets by 
proteinase-activated receptor 1 (PAR1) and PAR4. Platelet- platelet aggregation is mediated by fibrinogen or with 
high local blood pressure/shear forces by VWF-integrin αIIbβ3 interaction.  
Platelet–monocyte interaction is mediated by platelet surface P-selectin after platelet degranulation its cognate 
receptor, P-selectin glycoprotein ligand 1 (PSGL1). Antiplatelet treatments used in Malehmir*, Pfister* et al.9 are 
dual therapy with Aspirin-Clopidogrel and monotherapy with Ticagrelor. Other potential platelet targeted therapies 
are indicated in blue (approved therapies) and red (investigational therapies) (adapted from Malehmir59 and 
Michelson69).GPVI: glycoprotein VI, VWF: von Willebrand factor, GP1b: glycoprotein 1b, PAR1: proteinase-
activated receptor 1, P2Y1: P2Y purinoceptor 1, 5HT2A: 5-hydroxytryptamine 2A, 5-HT: 5- hydroxytryptamine, TP: 
thromboxane prostanoid, TXA2: thromboxane A2, COX1: cyclooxygenase 1, PSGL1: P-selectin glycoprotein ligand 
1, UFH: unfractionated heparin, AA: arachidonic acid; EP3, prostaglandin E2 receptor EP3 subtype; NO, nitric oxide; 
PDE, phosphodiesterase; PG, prostaglandin; PI3Kβ, phosphoinositide 3-kinase β-isoform, adapted from69. 
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5 Hypothesis and aims 
In the frame of this PhD thesis two main questions were addressed. First, what is the role of 
T-cells and TCR-associated signaling in NASH development and NASH-induced HCC. 
Second, how could the knowledge of hepatic inflammation driving NAFLD and NASH be used 
to understand mechanisms triggering inflammation as well as focusing to intervene 
therapeutically with the progression of NAFLD and NASH.  
 
Aim 1: Deciphering TCR signaling in metabolically activated T-cells in NASH and liver 
cancer development 
The first aim of this PhD thesis was to decipher the role of T-cells and TCR-associated 
signaling in NASH development and NASH-induced HCC by utilizing different genetic mouse 
models, genetic therapeutic and interventional antibody-based strategies.  
To address the hypothesis that specific dietary-activated subsets of CD8+ and NKT cells 
contribute mechanistically to the development of NASH and subsequently to HCC in a 
potentially antigen-mediated manner in a dietary mouse model, the following questions, aims 
and milestones were defined: 
1. Is the dietary activation of T-cells a consequence of NAFLD or of NASH-promoting 
mechanisms? Do different subsets of T-cells influence pathology development? 
2. Are there changes in the T-cell compartment upon progression of NASH pathology? 
3. Are T-cells and TCR-dependent mechanisms essential to induce NASH pathology and 
subsequent HCC development? 
4. Characterization of T-cell subsets at different stages of NASH pathology by antibody-
mediated manipulation. 
5. Does suppression of T-cell exhaustion in NASH prevent liver cancer formation? 
This study should allow an in-depth analysis of the role and the origin of T-cells in metabolic 
syndrome-induced hepatitis, NASH and HCC. Thus, it was envisaged, that the data would 
deepen current knowledge about the role of T-cells in NASH development and identify potential 
novel therapeutic targets, as well as allowing reevaluation of currently used and approved 
clinical antibodies (e.g. α-PD-1) in the context of NASH and NASH-triggered HCC diseases. 
 
Aim 2: Platelet GPIbα is a mediator and potential interventional target for NASH and 
subsequent liver cancer 
The second aim of this PhD thesis was to investigate if anti-platelet treatment (APT) could be 
used therapeutically to ameliorate NASH, as well as to decipher the role of platelets as 
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mediators of hepatic inflammation in NASH development by utilizing different therapeutic and 
interventional antibody-based strategies.  
To address the hypothesis that platelets are mediators of hepatic inflammation in NASH 
development and could be a potential interventional target the following questions, aims and 
milestones were defined: 
1. Is intrahepatic platelet abundance a result of NAFLD with induced insulin resistance 
or NASH diet feeding? 
2. Do therapeutic APT strategies have comparable beneficial effects to preventive APTs 
in established NASH? 
3. When do platelets home the liver during NASH diet feeding, and which other immune 
cells co-localize with platelets? 
4. What are the potential mechanisms of hepatic platelet homing in early NASH 
development and established NASH? 
5. Does therapeutic use of GPIbα antibody have other beneficial effects besides 
reduction of intrahepatic platelets? 
6. Does long-term CD-HFD feeding induce hepatocarcinogenesis in hIL4rα/GPIbα-Tg 
mice? 
This study allowed an in-depth analysis of the role of platelets in metabolic syndrome-induced 
hepatitis, NASH and HCC. Thus, the data deepened current knowledge about the role of 
platelets as markers of early liver damage in NASH development and identified platelet GPIbα 
as a potential interventional target in the context of NASH and NASH-triggered HCC diseases9. 
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6 Methods 
6.1 Mice, diets and treatments 
Adapted from Malehmir*, Pfister* et al.9: 4-6 weeks old male C57BL/6J mice were purchased 
from Charles River, and all strains of genetically-altered mice were on a C57BL/6J background. 
Control mice were matched by genetic background, age and sex. 
Mice were housed at the at the University Hospital Zurich (USZ), the Biomedical Services Unit 
at University of Birmingham or University of Newcastle, the University of Calgary and German 
Cancer Research Center (DKFZ). Animals were maintained under specific pathogen-free 
conditions and experiments were performed in accordance to German Law (G129/16, G7/17, 
55.2-1-54-2532-39-2015, G-91/14 and AZ:84-02.04.2014.A010). Further, experiments were 
performed in accordance to the UK Animals Scientific Procedures Act of 1986, with project 
license approval granted by the UK Home Office (project license P3F79C606) and the 
University of Calgary Animal Care Committee (protocol AC16-0148) in accordance with the 
Canadian Council for Animal Care Guidelines. 
6-8 week-old male mice were fed ad libitum: normal diet (ND), high fat diet (HFD) (Research 
Diets; D12451), choline-deficient high-fat diet (CD-HFD) (Research Diets; D05010402), 
western diet with trans-fat (WD-HTF) (Research Diets; D09100301 - 40 kcal % fat (Primex 
shortening), 20 kcal % fructose, 2% cholesterol). 
For interventional studies, male mice were fed CD-HFD for the indicated timeframes and 
treated with CD8 depleting antibody (Bioxcell, 2.43), NK1.1 depletion antibody (Bioxcell, 
PK136) or anti-PD-1 (Bioxcell, RMP1-14). At the end of the experiment, animals were 
sacrificed, and the liver, fat and serum harvested for analysis9. 
 
Adapted from Malehmir*, Pfister* et al.9: For therapeutic anti-platelet treatments, cohorts of 
mice fed CD-HFD or WD-HTF were treated with Ticagrelor (40μg/ ml drinking water; 
~3mg/kg/day). 
For studies deciphering early platelet homing mechanisms, 5-week-old male mice were fed 
ND, CD-HFD or WD-HTF for 3.5 weeks and subsequently treated for 2.5 weeks.  
Mice were treated intravenously in 100µl PBS either 20µg/mouse anti-CD44 blocking antibody 
(clone KM81, Cedarlane, CL8944AP) or 100µg/mouse anti-CD44 non-blocking antibody (clone 
IM7, Bioxcell, BE0039). For further deciphering of the role of early platelet homing by the 
CD44-hyaluronan axis, mice were treated intraperitoneally 20U/g murine hyaluronidase 
(HYAL) in 100µl PBS. 
For Kupffer cell depletion experiments mice were treated with 100µl/ mouse Clodrosome 
(liposomal clodronate), or as a control 100µl/mouse Encapsome (Control Liposomes).  
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For interventional GPIbα blocking experiments mice were treated intravenously in 100µl PBS 
either 100µg/mouse anti-GPIbα or 100µg/mouse Fab-Rat IgG (kindly provided by Bernhard 
Nieswandt, University of Wurzburg).  
In late treatment regimes, mice were fed CD-HFD for 6 months and treated with the same 
protocol for Kupffer cell depletion or interventional GPIbα blocking experiments for indicated 
time points9. 
 
Adapted from Malehmir*, Pfister* et al.9: For deciphering of the role of granulocytes in early 
phases of NASH, an osmotic pump experiment was performed in collaboration with Caroline 
L. Wilson, Jack Leslie and Derek A. Mann from Newcastle University. In this experiment, 5-
week-old male mice were fed a CD-HFD for 12 weeks. Four weeks after the diet started, mini 
pumps (Alzet, model 2004) were implanted subcutaneously into the mice to deliver 30μg per 
day of Ly6G (clone 1A8, Bioxcell, BP0075) neutrophil-depleting antibody or Rat IgG2a (clone 
2A3, Bioxcell, BE0089) for 8 more weeks. At the end of the experiment, animals were 
sacrificed, and the liver, fat and serum harvested for analysis9. 
 
6.2 Measurement of liver triglycerides 
Adapted from Malehmir*, Pfister* et al.9: Liver triglycerides were measured by crushing 20 - 50 
mg of tissue in liquid with a pestle and adding 250µl 0.9% NaCl. After incubation on heat block 
for 10min, RT, 450rpm, 250µl ethanolic 0.5KOH was added, samples were vortexed and 
incubated for 30min, 71°C, 450rpm. 500µl 0.15M MgSO4 was added, and samples were 
vortexed. After centrifugation for 10min, RT, 13,000g supernatants were collected and 
analyzed by using optical densitometry O.D. 505 with 1:4 diluted liver samples by GPO-PAP 
from Roche Diagnostics9. 
 
6.3 Intraperitoneal glucose tolerance test 
Adapted from Malehmir*, Pfister* et al.9: After overnight fasting, mice were i.p. injected with 
5µl/gr body weight of a 20% glucose solution, blood glucose was measured using “Accu-chek 
Performa Glucometer” at the indicated time intervals, by puncturing the lateral tail vein9. 
 
6.4 Intraperitoneal insulin tolerance test 
Adapted from Malehmir*, Pfister* et al.9: After mild fasting for 6 h, blood glucose concentrations 
were determined for each mouse before insulin (1U/g lean mass determined by EchoMRI 
analysis) administration using “Accu-chek Performa Glucometer”. Mice were i.p. injected with 
insulin and blood glucose was measured at the indicated time intervals by puncturing the lateral 
tail vein9. 
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6.5 Western blot analysis 
Adapted from Malehmir*, Pfister* et al.9: Liver homogenates were prepared using 
radioimmunoprecipitation assay (RIPA) buffer supplemented according to the manufacturer’s 
manual with complete protease inhibitor cocktail (Roche #11697498001) and phosphatase 
inhibitor (Sigma-Aldrich) in a gentleMACS™ Dissociator (Miltenyi Biotec). Protein 
concentrations were determined using the Pierce BCA Protein Assay Kit (Thermo Scientific) 
according to the manufacturer’s manual. 10μg of proteins were separated under reducing 
conditions (2.5% β-mercaptoethanol) by 10% gels and electrophoresis and blotted by wet 
blotting for 1.5h onto nitrocellulose membranes (Bio Rad). Membranes were blocked in 5% 
milk/PBS-T for 1h at RT. Primary antibodies (Table 2, all Cell Signaling) were incubated at 4°C 
overnight under shaking conditions. Incubation with the secondary antibody (Anti-Rabbit IgG 
(H+L) – HRP, 1:5000, W4011 Promega) was performed for 1h. Detection was performed by 
Clarity Western ECL Substrate (Bio Rad) with a ChemiDoc imaging system (BioRad). 
 
Table 2: Antibodies for Westernblot analysis 
Name Clone Cat # 
P-p38MAPK (Thr180/ Tyr182) D3F9 4511 
p38 MAPK D13E1 8690 
P-p65  Ser536 3033 
p65  D14E12 8242 
COX2  D5H5 12282 
GAPDH  14C10 2118 
 
6.6 Isolation and staining of lymphocytes for flow cytometry and FACS 
Adapted from Malehmir*, Pfister* et al.9: Mice were transcardially perfused with PBS, and livers 
were dissected. Livers were incubated for up to 35min in 37°C with digestion buffer (Collagen 
IV 1:10 (60 U f.c.) and DNase I 1:100 (25µg/ml f.c.)) and subsequently passed through a 
100µm filter. Livers were Washed with RPMI1640 (#11875093) medium and subsequently 
centrifuged for 7min/300g/4°C. Lymphocyte enrichment was achieved by a 2-step Percoll 
gradient (20ml 25% Percoll/HBSS underlay with 20ml 50% Percoll/HBSS) and centrifugation 
for 15min/1800g/4°C (Acc:1 Dcc:0). Leukocytes were collected, washed with HBSS, 
centrifuged for 10min/700g/4°C, counted and transferred to a 15ml Falcon for a final washing 
step with FACS buffer (PBS supplemented with v/v 0.4% 0.5M EDTA pH= 8 and w/v 0.5% 
albumin fraction V (#90604-29-8)). 
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Isolation of splenic lymphocytes was done by passing spleens through a 100µm mesh and 
subsequent washing. Afterwards, an erythrocyte lysis using ACK-buffer 1x 2ml for 5 min RT 
and then a wash was performed. 
Isolation of blood-derived lymphocytes was done by collection of blood in FACS buffer and 
performing erythrocyte lysis two times using ACK-buffer 1x 2ml for 5 min RT and then washing. 
For T-cell re-stimulation, cells were incubated for 2h, 37°C, 5% CO2 in RPMI 1640 
supplemented with v/v 2% fetal calf serum using 1:500 Biolegend´s Cell Activation Cocktail 
(with Brefeldin A) (#423304) and 1:1000 Monensin Solution (1,000X) (#420701). 
Staining was performed using Live/Dead discrimination by using DAPI or ZombieDyeNIR 
according to the manufacturer´s instructions. After washing (~400g, 5min, 4°C), cells were 
stained in 25µl of titrated antibody master mix for 20min at 4°C and washed again (antibodies 
shown in Table 3). Samples for flow cytometric activated cell sorting (FACS) were then sorted. 
Samples for flow cytometry were fixed using eBioscience IC fixation (#00-8222-49) or Foxp3 
Fix/Perm kit (#00-5523-00) according to the manufacturer´s instruction. Intracellular staining 
was performed in eBioscience Perm buffer (#00-8333-56). 
Cells were analyzed using BD FACSFortessa, Sony spectral analyzer SP6800 and data were 
analyzed using FlowJo. For sorting, a FACS Aria II and a FACSAria FUSION in collaboration 
with the DKFZ FACS core facility were used. 
The 24-color flow cytometric analysis was done in collaboration with Nicolas Nunez and 
Burkhard Becher from the University of Zurich75. 
 
Table 3: Flow cytometry antibodies 
Fluorochrome Name Clone Cat # 
Alexa700 CD4  RM4-5 100536 
Alexa700 CD45 30-F11 103128 
Alexa700 CD86  GL-1 105023 
Alexa647 FOXP3 150D 320014 
APC CD11b M1/70 101212 
APC CD11c N418 117309 
APC CD3  17A2 100236 
APC CD44 IM7 103012 
APC IFNy XMG1.2 505810 
APC CD366 RMT3-23 119706 
APC NK1.1  PK136 108710 
APC/Cy7 CD19  6D5 115530 
APC/Fire NK1.1  PK136 108751 
APC/Fire CD19  6D5 115557 
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APC/Fire CD3 17A2 100247 
FITC CD11b M1/70 101205 
FITC CD19  6D5 115505 
FITC CD25 3C7 558689 
FITC CD45 I3/2.3 147710 
FITC KLRG1 (MAFA) 2F1/KLRG1 138409 
FITC IL-10 JES5-16E3 505006 
FITC Ly- 6C  HK 1.4 128005 
FITC TCR γδ  UC7-13D5 107504 
FITC CD206 (MMR) C068C2 141704 
FITC NK1.1 PK136 108706 
PE CD274 10F.9G2 124307 
PE CD278 7E.17G9 117405 
PE CD69  H1.2F3 104508 
PE F4/80 BM8 123110 
PE Granzyme B NGZB 12-8898-80 
PE IL-17A  TC11-18H10.1 506904 
PE mCD1d/α- GalCer/PE  Immudex YD8002-PE 
PE TCR γδ  eBioGL3 12-5711-82 
PE CD223 (LAG-3) C9B7W 125208 
PE TNF-α  MO6-XT22 506306 
PE Perforin S16009A 154306 
PE/Cy7 CD3  17A2 100220 
PE/Cy7 Ly-6G (PE/Cy7) 1A8 127618 
PE/Cy7 NK1.1 PK136 108713 
PE/Cy7 F4/80 BM8 123114 
PE/Dazzle CD11c N418 117348 
PE/Dazzle CD279  RMP1-30 109116 
PE/Dazzle CD335 29A1.4 137630 
PE/Dazzle CD62L MEL-14 104448 
PE/Dazzle TNF-α  MP6-XT22 506346 
PE/Dazzle CD11c N418 117647 
PerCP/Cy5.5 CD8a  53-6.7 100734 
PerCP/Cy5.5 I-A/I-E  M5/114.15.2 107625 
PerCP/Cy5.5 LY-6C  HK1.4 128012 
  CD16/32  93 101302 
 
6.7 Electron microcopy 
Adapted from Malehmir*, Pfister* et al.9: In collaboration with Marco Prinz from the 
Universitätsklinikum Freiburg electron microscopy was performed. For this, sections from 
epon-embedded, glutaraldehyde-fixed liver samples were cut and stained with toluidine blue. 
34 
After trimming and ultrathin cutting of liver, tissues were treated with uranyl acetate and lead 
citrate as described previously76. For analysis analySIS Docu System (Soft Imaging System) 
was used9. 
 
6.8 Isolation of RNA and quantitative real-time PCR. 
Adapted from Malehmir*, Pfister* et al.9: Total RNA from whole liver homogenates was isolated 
from frozen liver tissues according to the manufacturer’s protocol using RNeasyMini Kit 
(Qiagen)9. The quantity and quality of the RNA was analyzed by Nanodrop analyzer (Thermo 
Scientific). For cDNA production 1μg of RNA was used by using Quantitect Reverse 
Transcription Kit (Qiagen) according to the manufacturer’s protocol9. qRT-PCR was performed 
in duplicates in a in 384-well plate using Fast Start SYBR Green Master Rox (Roche) with 
custom made primers purchased from Eurofins with a 7900 HT qRT-PCR system (Applied 
Biosystems, Life Technologies Darmstadt, Germany)9. 
 
6.9 Measurement of serum parameters  
Adapted from Malehmir*, Pfister* et al.9: Serum was isolated from the heart blood after 
sacrifice, and parameters were measured by using either a Fuji DRI-CHEM NX500i machine 
with commercially available test application from FUJIFILM for ALT, AST, cholesterol and 
triglycerides, or analyzing parameters on a Cobas Reader in collaboration with the Institute for 
Clinical Chemistry and Pathobiochemistry, TUM, Munich9. 
 
6.10 Histology, immunohistochemistry, scanning and automated analysis  
Adapted from Malehmir*, Pfister* et al.9: Tissues were fixed in 4% paraformaldehyde and 
paraffin-embedded in collaboration with Ruth Hillermann and Olga Seelbach at the Technical 
University of Munich (TUM) or in collaboration with Danijela Heide, Jenny Hetzer, Corinna 
Gropp, Katharina Kessler and Nathalie Klaumünzer at the DKFZ, Department of Chronic 
Inflammation and Cancer (Heidelberg). Briefly, 2μm sections from FFPE and cryo-preserved 
tissues were prepared and stained with Hematoxylin/Eosin or IHC antibodies on a Bond MAX 
(Leica) (Table 4). For Sudan Red staining, cryo sections (5µm) were cut and stained with 
Sudan Red (0.25% Sudan IV in ethanolic solution). Slides were scanned with SCN400 slide 
scanner (Leica) and analyzed either using for area based stainings Tissue IA image analysis 
software by Leica Biosystems Version 4.0.6, or macro-based analysis by ImageJ. NAFLD 
activity scoring (NAS) was performed on murine livers and cross-validated by pathological 
expertise9. 
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Table 4: IHC antibodies 
Target Dilution Clone Cat # 
MHCII 1:500 M5/114.15.2 NBP1-43312 
CD3 1:250 ab16669 ab16669 
F4/80 1:50 BM8 123105 
Collagen IV 1:50 CL50451AP-1 007CL50451AP 
Ki-67 1:200 RM-9106-S1 RM-9106-S1 
Ly6G 1:600 1A8 551459 
CD42b 1:200 SP219 ab183345 
 
6.11 Intravital microscopy 
Adapted from Malehmir*, Pfister* et al.9: In collaboration with Moritz Peiseler, Bas Surewaard 
and Paul Kubes from the University of Calgary, multichannel spinning-disk confocal 
microscopy was performed. After anesthetization of mice by i.p. administration of ketamine 
(200mg/kg body weight; Bayer Animal Health) and xylazine (10mg/kg body weight; Bimeda-
MTC), fluorescently conjugated antibodies and proteins to mark cells/structures of interest 
(Table 5), as well as additional anesthetics were administered by tail vein catheterization9. 
Exact mouse fixation and intravital microscopy setup are described in Malehmir*, Pfister* et 
al.9. Briefly, the mouse was placed on a heating plate to maintain 37°C and the liver was fixed 
to restrict movement by breathing and subsequent artefacts, before acquiring videos by an 
inverted spinning-disk confocal microscope (IX81; Olympus) with motorized drive and stage, 
controlled by Volocity software (Perkin Elmer). 
In vivo image analysis was performed by Volocity software (Perkin Elmer) and is described in 
detail in Malehmir*, Pfister* et al.9: 
 
Table 5: Antibodies used for intravital microscopy 
Fluorochrome Target Dilution Clone Cat # 
AF750 F4/80 2μg/mouse BM8 AbLab, custom made 
AF647 CD49b 3μg/mouse HMa2 103511 
PE Ly6G 3μg/mouse 1A8 127607 
FITC CD3e 2μg/mouse 145-2c11 11-0031-82 
AF555 (self-
labeled) HAPB 
 
 Sigma- Aldrich 
 
6.12 Immunofluorescence microscopy 
Adapted from Malehmir*, Pfister* et al.9: In collaboration with Donato Inverso from the DKFZ 
Heidelberg immunofluorescence microscopy was performed. Briefly, after perfusion of mice, 
livers were harvested, fixed for 16h, dehydrated in 30% sucrose, embedded in OCT and cut 
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into 25µm slices. After permeabilization and blocking with PBS containing 0.3% Triton X-100 
(Sigma-Aldrich) and 10% FBS, samples were stained with primary antibodies (Table 6). 
Stained slides were covered with fluorescence mounting medium (DAKO), pictures were taken 
with an inverted Leica microscope (TCS STED CW SP5, Leica Microsystems) and 3D 
reconstruction from z-stacks was performed by using Imaris (Bitplane) software9. 
 
Table 6: Antibodies used for immunofluorescence microscopy 
Target Dilution Clone Cat # 
CD41  1:100 MWReg-30 133906 
F4/80 1:100 BM8 17-4801-82 
B220 1:100 RA3-6B2 103226 
CD11b  1:100 M1/70 101212 
collagen IV 1:200  10808 
CD3 1:100  A0445229-2 
 
6.13 Statistical analyses  
Adapted from Malehmir*, Pfister* et al.9: Mouse data are presented as the mean±SEM. Pilot 
experiments and previously published results were used to estimate the sample size, such that 
appropriate statistical tests could yield significant results. Statistical analysis was performed 
using GraphPad Prism software version 7.03 (GraphPad Software). Data were analyzed by 
one way analysis of variance (ANOVA) with post hoc tests. When comparing multiple groups 
I used Tukey`s multiple comparison test, when I compared only two experimental groups I 
used Dunnett´s multiple comparison test. Multiple parameters were analyzed by two way 
ANOVA with Tukey`s or when comparing to one experimental group Sidak`s multiple 
comparison test post hoc test. Analysis of two samples was performed by two-tailed Student’s 
t test, and statistics for HCC incidence were calculated using Fisher’s exact test. Statistical 
significance is indicated as follows:*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.00019. 
  
37 
7 Results 
 
7.1 Aim 1: Deciphering TCR signaling in metabolically activated T-cells in 
NASH and liver cancer development 
7.1.1 NASH - a chronic disease with a defined T-cell phenotype 
Recent publications suggest a role of T-cell receptor (TCR)-dependent cells in the progression 
from a healthy mouse liver to a NAFL phenotype, NASH and eventually HCC induction6,31,36. 
Therefore, I sought to investigate whether in mouse models of NAFLD or NASH, TCR-
dependent cells are changed in their number, their activation and exhaustion status in early 
stages of pathology development, highlighting potential initiators and drivers of disease. 
Wildtype (WT) mice fed for 3 months an NAFLD-inducing high-fat diet (HFD) or a NASH-
inducing choline-deficient high fat (CD-HFD), developed significantly more body weight 
compared to normal chow diet (ND) mice (Figure 7a). Only CD-HFD fed mice developed liver 
damage (Figure 7b), which was not associated with an increase of hepatic triglycerides 
(Figure 7c). Further, markers of NASH pathology like macrovesicular steatosis and immune 
cell infiltration could be observed by H&E (Figure 7d) and in NAFLD activity scoring (NAS) 
(Figure 7e). No TCR-dependent cell increase was seen (Figure 7f); however, the hepatic 
immune cell compartment was polarized towards CD3+ and CD8+ T-cells, while CD4+ T-cells 
remained unchanged (Figure 7g). Further, in CD-HFD fed mice an increase of activated 
memory (CD44+CD69+) CD8+ T-cells was observed. The CD8+ T-cells were positive for 
interferon gamma (IFNy) and expressed markers of exhaustion (PD-1) (Figure 7g + h). 
Thus, I concluded that CD8+ T-cell activation and subsequent CD8+ T-cell exhaustion marker 
expression are specifically associated with a NASH-inducing diet, but not an NAFLD-inducing 
HFD alone. 
 
Next, I sought to characterize the changes in TCR-dependent cells over the progression of 
NASH pathology.  
3, 6 or 12-month CD-HFD mice showed significantly increased body weight (Figure 8a) and 
liver damage (Figure 8b) compared to ND fed mice. Further, the progression of pathology was 
associated with increased absolute numbers of hepatic CD45+CD3+ and CD3+CD8+ T-cells, 
but not CD3+CD4+, after 6 and 12 months of diet (Figure 8c). Further, these CD8+ T-cells 
expressed markers of exhaustion (PD-1) and activation (CD69) (Figure 8d, e, f). In line with 
more liver damage, immune cell infiltration and activation, H&E stainings and NAS evaluation 
indicated a progression of NASH pathology over time (Figure 9a). 
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In a second model of NASH based on 6 months of a Western-style diet (high cholesterol and 
high fructose) with high trans fats (WD-HTF) feeding, mice had a significantly increased body 
weight and liver damage (Figure 9b). Further, markers of NASH pathology (Figure 9c) and a 
similar T-cell polarization for activation and exhaustion to previously reported data (Figure 8a-
d) for CD-HFD fed mice (Figure 9d) were observed. 
Thus I concluded that prolonged NASH diet feeding leads to a phenotype of increased liver 
damage, progressive NASH development and CD8+ T-cell activation, as well as CD8+ T-cell 
exhaustion. 
 
 
Figure 7: Early phases of NASH induction are correlated with activated CD8+ T-cells 
(a) Body weight development of 3 months ND, HFD or CD-HFD fed mice. (n= 8 mice/group). Asterisks indicate 
significance of groups compared to ND fed mice. (b) ALT of mice shown in a. (ND n= 8 mice; CD-HFD n= 8 mice; 
HFD n= 7 mice). (c) Hepatic triglycerides of mice shown in a. (n= 8 mice/group). (d) H&E staining, with (e) NAS 
evaluation of mice shown in a. (ND n= 7 mice; CD-HFD n= 7 mice; HFD n= 5 mice). Scale bar: 50 µm. (f) 
Quantification in absolute numbers and (g) relative to CD45 of hepatic lymphocytes by flow cytometry of mice shown 
in a. (n= 4 mice/group). (h) Representative flow cytometry plots of data shown in g. (n= 4 mice/group). All data are 
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shown as mean ± SEM. All data were analyzed by one way ANOVA and Tukey`s multiple comparison test. *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001.  
 
Increased hepatic T-cell accumulation and higher CD69 and PD-1 expression indicated a 
specific T-cell reaction in a chronic model of dietary liver challenge; therefore, I investigated 
possible T-cell clonal outgrowth, potential antigen-driven T-cell activation and subsequent T-
cell expansion. 
Flow cytometric analysis of 15 TCR variable beta (TCR vβ) chains of hepatic isolated CD4+ 
and CD8+ T-cells showed, with one exception, preferential expression of TCR vβ 7 after 12 
months CD-HFD feeding and no significant differences between ND or CD-HFD fed mice after 
3, or 6 months (Figure 10a, b, c).  
 
Lymphocytes isolated from blood showed only small differences compared to changes 
observed in the liver in relative T-cell lymphocyte composition, CD4+ or CD8+ T-cell expression 
of markers for activation or exhaustion, or TCR vβ representation in ND or CD-HFD fed mice 
after 3, 6, or 12 months (Figure 11a-e). However, in blood, two TCR vβ chains, namely TCR 
vβ4 after 6 months and TCR vβ 3 after 12 months, showed significant differences between ND 
and CD-HFD fed mice (Figure 11d, e). 
 
Next, I investigated whether specific T-cell subsets are activated and subsequently express 
markers of exhaustion. Thus, I focused on hepatic CD8+PD-1+ T-cells. Indeed, several TCR 
vβ chains were significantly overrepresented in CD8+PD-1+ T-cells compared to the whole 
population of ND or CD-HFD-associated CD8+ T-cells (Figure 12a-c). Further, in 3, 6 and 12 
months CD-HFD fed mice, different TCR vβ chains are significantly or close to significantly 
overrepresented in the CD8+PD-1+ population, potentially indicating that different clones 
emerge at different progression states of NASH pathology (Figure 12a-c). 
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Figure 8: NASH: a progressive disease 
(a) Body weight development over 12 months of CD-HFD feeding. (n= 8 mice/group; but ND 6 months n= 7 
mice/group). (b) ALT development over time. (3 months ND n= 20 mice, 3 months CD-HFD n= 27 mice; 6 months 
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ND= 31 mice, 6 months CD-HFD n= 58 mice; 12 months ND= 18 mice, 12 months CD-HFD n= 69 mice). (c) 
Absolute quantification of hepatic lymphocytes by flow cytometry (3 months n= 7 mice/group; 6 months ND n= 13 
mice, CD-HFD n= 10 mice; 12 months n= 4 mice/group). (d) Polarization of hepatic lymphocytes by flow cytometry 
(3 months n= 4 mice/group; 6 months ND n= 11 mice, CD-HFD n= 16 mice; 12 months ND n= 4 mice, CD-HFD n= 
3 mice). (e) Representative flow cytometry plots of CD3+CD4+ and (f) CD3+CD8+ lymphocytes of mice shown in d. 
All data are shown as mean ± SEM. Data were analyzed by two way ANOVA and Sidak`s multiple comparison test 
or two-tailed Student T test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
 
 
Figure 9: Corroboration of NASH being a progressive disease  
(a) H&E staining and NAS evaluation (3 months n= 5 mice/group; 6 months n= 8 mice/group; 12 months ND n= 9 
mice, CD-HFD n= 12 mice). Scale bar: 50 µm. (b) Body weight and ALT concentrations of mice fed 6 months ND 
or WD-HTF (body weight: ND n= 13 mice, WD-HTF n= 16 mice; ALT: ND n= 15 mice, WD-HTF n= 16 mice). (c) 
H&E staining and NAS evaluation (ND n= 15 mice, WD-HTF n= 16 mice). Scale bar: 50 µm. (d) Polarization of 
hepatic lymphocytes by flow cytometry (ND n= 3 mice, WD-HTF n= 8 mice). All data are shown as mean ± SEM. 
Data were analyzed by two way ANOVA and Sidak`s multiple comparison test or two-tailed Student T test. *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001. 
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Figure 10: Hepatic T-cell clonal distribution 
(a) Flow cytometric analysis for TCR vβ expression of hepatic T-cells of 3, or (b) 6, or (c) 12 months ND or CD-HFD 
fed mice (n= 4 mice/group). All data are shown as mean ± SEM. Data were analyzed by two way ANOVA and 
Sidak`s multiple comparison test. *p<0.05. 
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Figure 11: NASH is associated with strong immunological changes in the liver, but to a lesser degree in 
blood 
(a) T-cells isolated from the blood of 3, 6 or 12 months ND or CD-HFD fed mice and (b) the expression of activation 
or exhaustion marker (n= 4 mice/group). (c) Analysis for TCR vβ expression of blood isolated T-cells of 3, or (d) 6, 
or (e) 12 months ND or CD-HFD fed mice (n= 4 mice/group). All data are shown as mean ± SEM. Data were 
analyzed by two way ANOVA and Sidak`s multiple comparison test. *p<0.05; **p<0.01; ***p<0.0001; ****p<0.0001. 
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Figure 12: Accumulation of clones positive for CD8+PD-1+ in progression of NASH pathology 
(a) Analysis for TCR vβ expression of hepatic whole population CD8+ T-cells or CD8+PD-1+ T-cells of 3, or (b) 6, or 
(c) 12 months ND or CD-HFD fed mice (n= 4 mice/group). All data are shown as mean ± SEM. Data were analyzed 
by two way ANOVA and Sidak`s multiple comparison test. *p<0.05; **p<0.01; ***p<0.0001; ****p<0.0001. 
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7.1.2 Dependency on a natural TCR repertoire and TCR-mediated effector function 
for NASH development 
After I observed differential representation of TCR vβ chains during the progression from 
healthy liver to NAFLD and further to NASH in hepatic CD8+PD-1+ T-cells, I next investigated 
the dependency on TCR abundance for NASH development, in general. 
TCRβδ-/-, lacking invariant innate-like TCRδ chain-dependent, as well as classical adaptive 
TCRβ-dependent T-cells, were fed CD-HFD for 6 months. CD-HFD fed TCRβδ-/- mice did have 
significantly less body weight (Figure 13a), were metabolically less impaired by intraperitoneal 
glucose tolerance test (IPGTT) (Figure 13b) and had significantly less liver damage compared 
to CD-HFD WT mice (Figure 13c). Further, CD-HFD TCRβδ-/- lacked histopathological signs 
of NASH on H&E staining, had no CD3+ cells, no Kupffer cell cluster formation and lacked 
fibrosis development (Figure 13d, e).  
Thus, I concluded that TCRβδ cells and therefore TCR abundance are essential for NASH 
development. 
 
Next, I investigated whether a natural TCR repertoire is necessary for inducing NASH 
pathology. To this end, OT-1 mice, which have transgenic expression of a chicken ovalbumin 
reactive TCR and thus a strongly CD8 polarized T-cell compartment, were put under 6 months 
CD-HFD. CD-HFD fed OT-1 mice did have significantly less body weight (Figure 14a), were 
metabolically equally impaired by IPGTT (Figure 14b) and had significantly less liver damage 
compared to CD-HFD fed WT mice (Figure 14c). Further, CD-HFD fed OT-1 lacked 
histopathological signs of NASH on H&E staining, had more CD3+ cells and no Kupffer cell 
cluster formation (Figure 14d, e).  
Thus, I concluded, that without a natural TCR repertoire, mice lacked liver pathological signs 
of NASH development and therefore a natural TCR repertoire is essential for driving NASH. 
 
Next, I sought to decipher in which way a natural functional TCR repertoire influences the 
induction of NASH. To this end, I fed CD-HFD to perforin knockout mice (Prf1-/-), lacking 
systemically the pore forming protein perforin and thus have a TCR effector function 
impairment. 
6 months CD-HFD fed Prf1-/- mice developed body weight comparable to WT CD-HFD fed 
mice (Figure 15a), were metabolically not impaired by IPGTT (Figure 15b) and had 
significantly less liver damage compared to CD-HFD WT mice (Figure 15c). Further, after 6 
months of CD-HFD feeding, Prf1-/- mice lacked or had ameliorated histopathological signs of 
NASH on H&E staining, had fewer hepatic CD3+ cells, less Kupffer cell cluster formation and 
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comparable levels of fibrosis and Ki-67 proliferating cells to WT ND (Figure 15d, e). Further, 
activated hepatic CD8+CD62L-CD44+CD69+ were significantly reduced in Prf1-/- CD-HFD fed 
mice, as well as hepatic CD8+PD-1+ T-cells (Figure 15f, g). These CD8+ T-cells were 
previously identified to be drivers of NASH pathology6. Further, in the frame of this thesis, 
accumulation of hepatic CD8+C69+ and CD8+PD-1+ T-cells correlated with progression of 
NAFLD and NASH pathology. 
Thus, I concluded that early phases of NASH development are dependent on TCR effector 
function. 
 
 
Figure 13: NASH development is dependent on TCR abundance 
(a) Body weight development of WT ND, WT CD-HFD or TCRβδ-/- CD-HFD fed mice (ND n= 4 mice; CD-HFD n= 6 
mice; TCRβδ-/- CD-HFD n= 6 mice). Asterisks indicate significance of groups compared to WT CD-HFD fed mice. 
(b) IPGTT of mice shown in a (ND n= 6 mice; CD-HFD n= 8 mice; TCRβδ-/- CD-HFD n= 3 mice). (c) ALT of mice 
shown in a. (ND n= 4 mice; CD-HFD n= 4 mice; TCRβδ-/- CD-HFD n= 3 mice). (d) H&E, CD3, F4/80 and Sirius Red 
staining with (e) NAS evaluation and quantification of mice shown in a. (H&E: ND n= 4 mice; CD-HFD n= 4 mice; 
TCRβδ-/- CD-HFD n= 3 mice; CD3: ND n= 5 mice; CD-HFD n= 5 mice; TCRβδ-/- CD-HFD n= 3 mice; F4/80 and 
Sirius red: n= 3 mice/group). Scale bar: 50 µm. All data are shown as mean ± SEM. All data were analyzed by one 
or two way ANOVA and Tukey`s multiple comparison test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.  
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Figure 14: A natural TCR repertoire is essential for NASH development 
(a) Body weight development of WT ND, WT CD-HFD or OT-1 CD-HFD fed mice (ND n= 3 mice; CD-HFD n= 6 
mice; OT-1 CD-HFD n= 10 mice). Asterisks indicate significance of groups compared to WT CD-HFD fed mice. (b) 
IPGTT of mice shown in a (ND n= 3 mice; CD-HFD n= 3 mice; OT-1 CD-HFD n= 6 mice). (c) ALT of mice shown in 
a. (ND n= 5 mice; CD-HFD n= 7 mice; OT-1 CD-HFD n= 9 mice). (d) H&E, CD3 and F4/80 staining with (e) NAS 
evaluation and quantification of mice shown in a. (H&E: n= 8 mice/group; CD3 and F4/80: n= 3 mice/group). Scale 
bar: 50 µm. All data are shown as mean ± SEM. All data were analyzed by one or two way ANOVA and Tukey`s 
multiple comparison test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.  
 
Due to the fact that some CD-HFD fed Prf1-/- mice developed histopathological signs of NAFLD 
and trends for increased ALT, indicative of liver damage, I investigated the lack of perforin in 
12 months long-term CD-HFD feeding, a time point at which WT mice develop tumors with an 
incidence of 25%6. 
12 months CD-HFD fed Prf1-/- mice developed body weight comparable to WT CD-HFD fed 
mice (Figure 16a), had no difference in liver damage compared to CD-HFD fed WT mice 
(Figure 16b) and had histopathological signs of established NASH on H&E staining (Figure 
16c, d). Further, 12 months CD-HFD fed Prf1-/- developed tumors with an incidence 
comparable to WT CD-HFD fed mice (Figure 16d, e). 
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Thus, I concluded the delay of NASH pathology initiation by an impaired TCR effector function 
does not translate to a significantly lower tumor incidence in long-term CD-HFD feeding 
experiments. 
 
 
Figure 15: Lack of TCR effector function delays NASH development 
(a) Body weight development of 6 months WT ND, WT CD-HFD or Prf1-/- CD-HFD fed mice (ND n= 6 mice; CD-
HFD n= 9 mice; Prf1-/- CD-HFD n= 18 mice). Asterisks indicate significance of groups compared to WT ND fed 
mice. (b) IPGTT of mice shown in a (ND n= 3 mice; CD-HFD n= 9 mice; Prf1-/- CD-HFD n= 6 mice). (c) ALT of mice 
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shown in a. (ND n= 11 mice; CD-HFD n= 18 mice; Prf1-/- CD-HFD n= 9 mice). (d) H&E, CD3, F4/80, Sirius Red and 
Ki-67 staining with (e) NAS evaluation and quantification of mice shown in a. (H&E: ND n= 6 mice, CD-HFD n= 6 
mice, Prf1-/- CD-HFD n= 5 mice; CD3: ND n= 5 mice, CD-HFD n= 5 mice, Prf1-/- CD-HFD n= 4 mice; F4/80: n= 5 
mice/group; Ki-67: ND n= 6 mice, CD-HFD n= 6 mice, Prf1- /- CD-HFD n= 5 mice). Scale bar: 50 µm. (f) Flow 
cytometry plots and (g) quantification of mice shown in a (ND n= 9 mice, CD-HFD n= 9 mice, Prf1-/- CD-HFD n= 5 
mice). (g) Flow cytometric quantification of mice shown in a (ND n= 6 mice, CD-HFD n= 6 mice, Prf1-/- CD-HFD n= 
5 mice). All data are shown as mean ± SEM. All data were analyzed by one or two way ANOVA and Tukey`s 
multiple comparison test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.  
 
 
Figure 16: Impaired TCR effector function has no influence on dietary tumor formation 
(a) Body weight development of 12 months WT or Prf1-/- CD-HFD fed mice (CD-HFD n= 10 mice; Prf1-/- CD-HFD 
n= 8 mice). (b) ALT of mice shown in a, with WT ND as a baseline of aged animals. (ND n= 6 mice; CD-HFD n= 9 
mice; Prf1-/- CD-HFD n= 7 mice). (c) NAS evaluation and (d) H&E staining of mice shown in a. (n= 6 mice/group). 
Scale bar: 50µm. (e) Tumor incidence of mice groups shown in a (CD-HFD n= 14 tumors in 37 mice, Prf1-/- CD-
HFD n= 7 tumors in 18 mice). All data are shown as mean ± SEM. All data were analyzed by one way ANOVA and 
Tukey`s multiple comparison test, by two-tailed Student T test, or by Fisher`s exact test. *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001.  
 
To determine whether T-cell effector impairment is the main driver of the observed delay of 
NASH in the systemic Prf1-/- mice, I investigated the role of natural killer T-cells (NKT) in NASH 
development and subsequent tumor formation. NKT type I cells mainly mediate cytotoxicity by 
using perforin. 
To this end, I used Jα18-/- mice lacking the Jα281 TCR and therefore lacking NKT type I cells 
reactive to the glycolipid alpha-galactosyl ceramide (α-Gal), and fed these mice CD-HFD for 6 
or 12 months. 
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After 6 months of CD-HFD feeding, Jα18-/- and WT control mice had no significant differences 
in body weight development (Figure 17a) and were metabolically significantly less impaired 
compared to WT CD-HFD fed mice by IPGTT (Figure 17b). CD-HFD fed Jα18-/- had liver 
damage similar to WT CD-HFD fed mice (Figure 17c) and no difference in histological 
evaluation of NASH pathology (Figure 17d). The lack of α-Gal NKT cells was confirmed by 
flow cytometric analysis (Figure 17e).  
Next, I investigated whether the lack of NKT type I cells has any influence on tumor formation 
despite the underlying NASH pathology. Upon 12 months CD-HFD feeding to WT and Jα18-/- 
mice, Jα18-/- mice developed higher body weight (Figure 17f), similar liver damage (Figure 
17g) and a similar histological evaluation of NASH by H&E staining (Figure 17h, i). Further, 
12 months CD-HFD fed Jα18-/- mice developed tumors (Figure 17j). 
Thus, I concluded lack of NKT type I cells cannot prevent NASH development and subsequent 
cannot prevent tumor formation upon long-term CD-HFD feeding. 
 
To further test the potential role of the NKT compartment in NASH pathology, I next 
investigated whether a lack of all NKT cells would affect NASH pathology and subsequent 
tumor formation.  
Thus, I used in collaboration with Manfred Kopf from the ETH Zurich CD1d-/- mice, lacking the 
antigen presenting protein CD1d and therefore have no invariant T-cells, namely NKT type I 
and NKT type II. In contrast to NKT type I cells, NKT type II cells` effector function is the release 
of cytokines. NKT type II cells, which are increased in dietary situations6, an effect which I also 
observed (Figure 17e), can concert their activity with other immune cells, like, for example, 
the previously described hepatic C69+CD8+ and PD-1+CD8+ T-cells. 
After 6 months of CD-HFD feeding, CD1d-/- and heterozygous control CD1d+/- mice had no 
significant difference in body weight (Figure 18a), no difference in liver damage (Figure 18b) 
and no difference in histopathological evaluation of NASH (Figure 18c). Further, WT and 
CD1d-/- 12 months CD-HFD fed mice developed the similar body weight (Figure 18d), similar 
liver damage (Figure 18e) and similar histological evaluation of NASH by H&E staining (Figure 
18f). Both WT and CD1d-/- 12 months CD-HFD fed mice developed tumors (Figure 18g). 
Thus, I concluded that lack of NKT type I and type II cells cannot prevent NASH development 
and lead subsequently to tumor formation upon long-term CD-HFD feeding. 
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Figure 17: Lack of NKT type I cannot prevent NASH development and subsequent tumor formation 
(a) Body weight development of 6 months WT ND, WT or Jα18-/- CD-HFD fed mice (WT ND n= 9 mice; WT CD-
HFD n= 14 mice; Jα18-/- CD-HFD n= 15 mice). (b) IPGTT of mice shown in a (WT ND n= 5 mice; WT CD-HFD n= 
8 mice; Jα18-/- CD-HFD n= 3 mice). (c) ALT of mice shown in a (WT ND n= 8 mice; WT CD-HFD n= 14 mice; Jα18- /- 
CD-HFD n= 10 mice). (d) H&E staining and NAS evaluation of mice shown in a. (n= 7 mice/group). Scale bar: 50µm. 
(e) Flow cytometric analysis of hepatic NKT type I/II ratio (n= 6 mice/group). (f) Body weight of WT or Jα18-/- 12 
months CD-HFD fed mice (WT CD-HFD n= 10 mice; Jα18-/- CD-HFD n= 23 mice). (g) ALT of mice shown in f. WT 
ND shown as a baseline for aged mice (WT ND n= 6 mice; WT CD-HFD n= 13 mice; Jα18-/- CD-HFD n= 13 mice). 
(h) NAS evaluation and (i) H&E staining of mice shown in f. (WT CD-HFD n= 14 mice; Jα18-/- CD-HFD n= 13 mice). 
Scale bar: 50µm. (j) Tumor incidence of mice groups shown in f (WT CD-HFD n= 14 tumors in 37 mice; Jα18-/- CD-
HFD n= 8 tumors in 27 mice). All data are shown as mean ± SEM. All data were analyzed by one or two way 
ANOVA and Tukey`s multiple comparison test, by two-tailed Student T test, or by Fisher`s exact test. *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001.  
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Figure 18: Lack of invariant NKT type I and II cannot prevent NASH development and subsequent tumor 
formation 
(a) Body weight development of CD1d+/- or CD1d-/- 6 months CD-HFD fed mice (CD1d+/- CD-HFD n= 11 mice; 
CD1d-/- CD-HFD n= 13 mice). (b) ALT of mice shown in a. (CD1d+/- CD-HFD n= 10 mice; CD1d-/- CD-HFD n= 13 
mice). (c) H&E staining and NAS evaluation of mice shown in a. (CD1d+/- CD-HFD n= 11 mice; CD1d-/- CD-HFD n= 
13 mice). Scale bar: 50µm. (d) Body weight development of WT or CD1d-/- 12 months CD-HFD fed mice (WT CD-
HFD n= 10 mice; CD1d-/- CD-HFD n= 11 mice). (e) ALT of mice shown in d. (WT CD-HFD n= 10 mice; CD1d-/- CD-
HFD n= 11 mice). (f) H&E staining and NAS evaluation of mice shown in d. (n= 10 mice/group). Scale bar: 50µm. 
(g) Tumor incidence of mice groups shown in d (WT CD-HFD n= 3 tumors in 10 mice; CD1d-/- CD-HFD n= 1 tumor 
in 11 mice). All data are shown as mean ± SEM. All data were analyzed by two-tailed Student T test, or Fisher’s 
exact test. 
 
7.1.3 Differential role of T-cells during NASH and subsequent tumor development 
My data so far indicated that the progression process of NAFLD to NASH development is 
strongly correlated to an activated and exhausted CD8+ T-cell phenotype and a natural TCR 
repertoire with intact TCR effector function. To decipher the contribution of CD8+ T-cells at 
different progression states of NASH pathology with the observed phenotype, I put WT mice 
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on CD-HFD for 4 months and treated these mice either with CD8 depleting antibody or 
checkpoint inhibition PD-1 blocking antibody with continuous CD-HFD diet for 8 weeks. 
After 6 months of ND or CD-HFD feeding and 8 weeks of treatment, the CD-HFD fed mouse 
groups had no significant difference in body weight (Figure 19a), but CD8 depleted mice had 
significantly increased liver damage compared to control-treated CD-HFD fed mice (Figure 
19b). The different treatment groups developed no difference in histopathological evaluation 
of NASH (Figure 19c, d). To define the immune compartments in more detail, analysis by flow 
cytometry showed an absolute cell number increase of α-PD-1 treated mice both in CD3+ and 
CD8+ T-cells, while CD8 depleted mice showed a significant reduction in CD8+ T-cells (Figure 
19e). Further, the composition of all living CD45+ cells changed significantly between 
treatments, namely CD8 depleted mice showed a significant decrease in CD3+ and CD8+ T-
cells, while other immune cells were left unchanged in terms of relative abundance (Figure 
19f, h). In contrast, α-PD-1 treated mice had a significant increase in CD8+ T-cells and a 
decrease in CD19+ B-cells, while other immune cells were again left unchanged in terms of 
relative abundance (Figure 19f, h). Both treatments resulted in more CD8+ T-cells expressing 
PD-1+ cells compared to CD-HFD fed control mice (Figure 19g). However, CD8 depletion 
reduced naive CD62L+, as well as memory CD62L-CD44+ or activated memory CD62L-
CD44+CD69+ CD8+ T-cells (Figure 19i). Treatment by α-PD-1 increased significantly CD62L-
CD44+CD8+ T-cells (Figure 19i). Focusing on potentially cytotoxic molecules mediating liver 
damage, compared to CD-HFD fed control mice, the T-cells populations of remaining CD8+ T-
cells upon CD8 depletion and the α-PD-1 treated CD8+ T-cells, had more GzmB-positive CD8+ 
T-cells (Figure 19j). Nevertheless, fewer of the remaining CD8+ T-cells upon CD8 depletion 
were positive for IFNy, and no significant differences between the groups for TNF-a was 
detected (Figure 19j). To test if more cells express GzmB+ or if individual T-cells express 
higher levels of GzmB+ per cell, indicative of high cytotoxic potential, I analyzed the levels of 
GzmB expression in CD4+ and CD8+ T-cells. Indeed, upon α-PD-1 treatment, CD4+ and CD8+ 
T-cells express higher levels of GzmB (Figure 19k). Further, the remaining CD8+ T-cells upon 
CD8 depletion expressed high levels of GzmB, as well (Figure 19k). Next, I investigated 
potential side effects of both treatments. First, potential compensatory reactions of CD4+ T-
cells upon CD8 depletion or second, overreaction or reactivation upon α-PD-1 treatment of 
CD4+ T-cells. However, both treatments had, aside from the increase of GzmB expression 
upon α-PD-1 treatment (Figure 19k), no significant effect on CD4+ T-cells (Figure 19h, l). Also 
the ratio of type I to type II NKT cells was not changed compared to CD-HFD control mice 
(Figure 19m). Alternatively, innate immune system cells could play an important role in 
mediating the observed effects of higher liver damage. However, KC, CD11b+, and myeloid 
dendritic cells (mDCs) showed no increase in MHC II expression, a marker of myeloid 
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activation (Figure 19n). However, upon CD8 depletion more plasmacytoid dendritic cells 
(pDCs) express MHC II compared to control CD-HFD fed mice (Figure 19n). 
Thus, I concluded CD8 depletion and α-PD-1 treatment worked effectively in mice in an 8 week 
treatment scheme and that CD8 depletion induces liver damage in NASH development at the 
stages of 4 to 6 months of CD-HFD feeding. 
 
7.1.4 Immunological profiling of hepatic tumor-associated lymphocytes 
To focus more on the potential translational aspects of this study, I investigated advanced 
NASH to HCC time points, because most patients will be diagnosed in advanced stages of 
NASH. Therefore, understanding the role of T-cells in this progressed pathology state of NASH 
is important and may have strong clinical implications.  
Thus, I fed WT mice CD-HFD for 10 months to induce an advanced liver pathology and treated 
these mice with CD8 depleting antibody for 8 weeks while continuously feeding CD-HFD diet. 
After 12 months of ND or CD-HFD feeding followed by 8 weeks of treatment, the CD-HFD fed 
mouse groups had no significant difference in body weight (Figure 20a). CD8 depleted mice 
had a no difference in ALT levels (Figure 20b) and were metabolically equally impaired by 
IPGTT compared to control-treated CD-HFD fed mice (Figure 20c). In contrast, CD8 depleted 
mice had weaker signs of NASH pathology, ameliorated fibrogenesis and reduced tumor 
burden (Figure 20d, e, f). To define the immune compartment in more detail, analysis by flow 
cytometry showed an absolute cell number decrease in CD8 depleted mice for hepatic CD45+, 
CD3+, CD8+ and CD19+ cells (Figure 20g, h). Further, the composition of all hepatic CD45+ 
cells changed, namely I saw reduced CD3+ and CD8+ T-cells in α-CD8 treated mice (Figure 
20h, i). I could not observe differences in the CD4+ T-cell compartment in terms of abundance 
(Figure 20g, h, i), polarization (Figure 20j) or effector molecules between α-CD8 treated and 
control mice (Figure 20k). Further, MHC II+ innate immune cells were unchanged (Figure 20l). 
Thus, I concluded that CD8 depletion in advanced stages of NASH pathology reduced CD8+ 
T-cells numbers, ameliorated liver pathology and tumor formation, but did not decrease ALT 
levels. 
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Figure 19: Functional antibody-mediated treatments fail to rescue NASH 
(a) Body weight of 6 months ND, or CD-HFD fed mice, treated 2x per week for 8 weeks with either PBS, α-CD8 or 
α-PD-1 antibodies (ND n= 8 mice; PBS + CD-HFD n= 6 mice; α-CD8 + CD-HFD n= 6 mice; α-PD-1 + CD-HFD n= 
3 mice). (b) ALT of mice shown in a (ND n= 8 mice; PBS + CD-HFD n= 6 mice; α-CD8 + CD-HFD n= 6 mice; α-PD-
1 + CD-HFD n= 3 mice). (c) NAS evaluation and (d) H&E staining of mice shown in a. (ND n= 8 mice; PBS + CD-
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HFD n= 6 mice; α-CD8 + CD-HFD n= 6 mice; α-PD-1 + CD-HFD n= 3 mice). Scale bar: 50µm. (e) Absolute flow 
cytometric analysis of hepatic T-cells (ND n= 4 mice; PBS + CD-HFD n= 3 mice; α-CD8 + CD-HFD n= 5 mice; α-
PD-1 + CD-HFD n= 3 mice). (f) Flow cytometric analysis of hepatic CD45+ cells (ND n= 8 mice; PBS + CD-HFD n= 
6 mice; α-CD8 + CD-HFD n= 5 mice; α-PD-1 + CD-HFD n= 3 mice). (g) Flow cytometric analysis of hepatic CD3+ 
T-cells (ND n= 8 mice; PBS + CD-HFD n= 6 mice; α-CD8 + CD-HFD n= 5 mice; α-PD-1 + CD-HFD n= 3 mice). (h) 
Flow cytometric plots of CD3+ T-cells. (i) Flow cytometric analysis of hepatic CD3+CD8+T-cells for T-cell activation 
and (j) positive cells for effector molecules (ND n= 8 mice; PBS + CD-HFD n= 6 mice; α-CD8 + CD-HFD n= 5 mice; 
α-PD-1 + CD-HFD n= 3 mice). (k) Flow cytometric analysis for GzmB expression in hepatic CD3+ T-cells (ND n= 8 
mice; PBS + CD-HFD n= 6 mice; α-CD8 + CD-HFD n= 5 mice; α-PD-1 + CD-HFD n= 3 mice). (l) Flow cytometric 
analysis of hepatic CD3+CD4+T-cells for T-cell activation (ND n= 8 mice; PBS + CD-HFD n= 6 mice; α-CD8 + CD-
HFD n= 5 mice; α-PD-1 + CD-HFD n= 3 mice). (m) Flow cytometric analysis of hepatic NKT type I/II ratio (ND n= 8 
mice; PBS + CD-HFD n= 6 mice; α-CD8 + CD-HFD n= 5 mice; α-PD-1 + CD-HFD n= 3 mice). (n) Flow cytometric 
analysis of hepatic innate immune system cells (ND n= 8 mice; PBS + CD-HFD n= 6 mice; α-CD8 + CD-HFD n= 5 
mice; α-PD-1 + CD-HFD n= 3 mice). All data are shown as mean ± SEM. All data were analyzed by one or two way 
ANOVA and Tukey`s multiple comparison test or when comparing only to one group or Sidak`s multiple comparison 
test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
 
Next, I tried to determine by immunological phenotyping why CD8 depletion abrogates tumor 
formation but not liver damage. 
Upon CD8 depletion, fewer hepatic naive, memory effector and memory CD8+ T-cells were 
detected (Figure 21a). These remaining CD8+ cells, as well as the CD4+ T-cell compartment, 
had similar exhaustion marker expression (Figure 21b). More of the non-depleted CD8+ T-
cells expressed Fas ligand (FasL) and expressed higher amounts of GzmB compared to 
control mice (Figure 21c, d). Other cell types which could potentially mediate liver damage 
are NK and NKT cells. CD8 depleted mice had no difference in their expression for effector 
molecules in NK cells (Figure 21e), but fewer NKT cells expressed IFNy without changes in 
TNF-a or perforin expression (Figure 21f). The NKT type I to type II ratio was not significantly 
changed upon CD8 depletion (Figure 21g). 
Of note, I depleted mice by α-CD8 and α-NK1.1 antibodies, to address a potential role of a 
concerted CD8+ NK1.1+ cell mechanism in driving liver damage. However, CD8/NK1.1 
depleted mice had no difference in body weight (Figure 21h), liver damage (Figure 21i), NAS 
evaluation (Figure 21j) and no tumors could be detected upon successful antibody mediated 
depletion. 
Thus, I concluded although low in numbers the remaining hepatic CD8+ T-cells expressed FasL 
and higher GzmB - markers of potential cytotoxic mediation. Similar to the previously reported 
data of knockout mice for NK and NKT cells, I could not detect an amelioration of advanced 
NASH pathology with α-CD8/NK1.1 co-treatment. 
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Figure 20: CD8+ T-cells drive tumorigenesis in advanced stages of NASH pathology 
(a) Body weight of 12 months ND, or CD-HFD fed mice, treated 2x per week for 8 weeks with IgG or α-CD8 
antibodies (ND n= 8 mice; control CD-HFD n= 23 mice; α-CD8 + CD-HFD n= 22 mice). (b) ALT of mouse groups 
shown in a (ND n= 9 mice; control CD-HFD n= 31 mice; α-CD8 + CD-HFD n= 22 mice). (c) IPGTT of mouse groups 
shown in a (control CD-HFD n= 8 mice; α-CD8 + CD-HFD n= 10 mice). (d) H&E and Sirius Red staining with (e) 
NAS evaluation and Sirius Red quantification of mouse groups shown in a (H&E: ND n= 11 mice; control CD-HFD 
n= 28 mice; α-CD8 + CD-HFD n= 23 mice; Sirius Red: ND n= 12 mice; control CD-HFD n= 21 mice; α-CD8 + CD-
HFD n= 17 mice). Scale bar: 50µm. (f) Tumor incidence of mouse groups shown in a (control CD-HFD n= 27 tumors 
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in 74 mice; α-CD8 + CD-HFD n= 1 tumor in 21 mice). (g) Absolute flow cytometric analysis of hepatic immune cells 
(control CD-HFD n= 10 mice; α-CD8 + CD-HFD n= 14 mice). (h) Flow cytometric plots of CD3+ T-cells. (i) Flow 
cytometric analysis of hepatic CD45+ cells (control + CD-HFD n= 11 mice; α-CD8 + CD-HFD n= 14 mice). (j) Flow 
cytometric analysis for polarization of hepatic CD4+ T-cells (control + CD-HFD n= 11 mice; α-CD8 + CD-HFD n= 14 
mice). (k) Flow cytometric analysis for effector molecules of hepatic CD4+ T-cells (control + CD-HFD n= 11 mice; 
α-CD8 + CD-HFD n= 14 mice). (l) Flow cytometric analysis of hepatic innate immune system cells (control + CD-
HFD n= 10 mice; α-CD8 + CD-HFD n= 14 mice). All data are shown as mean ± SEM. All data were analyzed by 
one way ANOVA and Tukey`s multiple comparison test, or two way ANOVA and Sidak`s multiple comparison test, 
or for tumor incidence Fisher’s exact test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
 
Next, I investigated the effects of interfering with the inhibitory axis of T-cell signaling by PD-
1/PD-L1 for PD-1+ cells in advanced stages of NASH pathology by administering α-PD-1 
blocking antibody. 
Thus, I fed WT mice CD-HFD for 10 months to induce a strong liver pathology and treated 
these mice with α-PD-1 blocking antibody for 8 weeks while continuously feeding CD-HFD diet. 
After 12 months CD-HFD feeding with 8 weeks of treatment the CD-HFD fed mouse groups 
had no significant difference in body weight (Figure 22a). Treatment with α-PD-1 increased 
AST and ALT levels significantly (Figure 22b), but affected glucose tolerance only mildly 
compared to control-treated CD-HFD fed mice (Figure 22c). Further, compared to control, CD-
HFD fed mice and α-PD-1 treated mice had increased NAS, similar levels of fibrosis and 
increased tumor burden (Figure 22d, e, f). To decipher the immune compartment in more 
detail, analysis by flow cytometry showed no difference in absolute cell numbers (Figure 22g), 
nor in the composition of all hepatic CD45+ cells upon α-PD-1 treatment (Figure 22h). 
Nevertheless, α-PD-1 treatment increased the amount of hepatic effector memory CD8+ T-
cells (Figure 22i). Further, analysis of three independent experiments indicated that, upon α-
PD-1 treatment, more CD8+ T-cells are positive for the effector molecules GzmB and IFNy 
(Figure 22j). Also, α-PD-1 treatment correlated with more PD-1+CD8+ T-cells and trends 
toward higher numbers of PD-1+CD4+ T-cells (Figure 22k), but no differences in FasL+ T-cells 
(Figure 22l). 
Thus, I concluded that α-PD-1 treatment in advanced stages of NASH pathology likely induced 
immune-related adverse events (irAEs) leading to increased liver damage, tumor or lesion 
formation and increased effector function markers on CD8+ T-cells. 
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Figure 21: Understanding high ALT in CD8 depleted mice with advanced NASH 
(a) Flow cytometric analysis for polarization of hepatic CD8+ T-cells isolated from mice 12 months fed ND, or CD-
HFD and treated 2x per week for 8 weeks with IgG or α-CD8 antibodies (control + CD-HFD n= 11 mice; α-CD8 + 
CD-HFD n= 14 mice). (b) Flow cytometric analysis of markers of hepatic T-cell exhaustion (control + CD-HFD n= 4 
mice; α-CD8 + CD-HFD n= 5 mice). (c) Flow cytometric analysis of FasL T-cell polarization (control + CD-HFD n= 
4 mice; α-CD8 + CD-HFD n= 5 mice). (d) Flow cytometric analysis for GzmB expression in hepatic CD3+ T-cells 
(control + CD-HFD n= 8 mice; α-CD8 + CD-HFD n= 10 mice). (e) Flow cytometric analysis for effector molecules of 
hepatic NK and (f) NKT cells (control + CD-HFD n= 4 mice; α-CD8 + CD-HFD n= 5 mice). (g) Flow cytometric 
analysis of hepatic NKT type I/II ratio (control + CD-HFD n= 6 mice; α-CD8 + CD-HFD n= 9 mice). (h) Body weight 
of 12 months fed ND, or CD-HFD fed mice, treated 2x per week for 8 weeks with IgG, α-CD8, or α-CD8/α-NK1.1 
antibodies (ND n= 8 mice; control CD-HFD n= 23 mice; α-CD8 + CD-HFD n= 22 mice; α-CD8/α-NK1.1 + CD-HFD 
n= 8 mice). (i) ALT of mouse groups shown in h (ND n= 9 mice; control CD-HFD n= 31 mice; α-CD8 + CD-HFD n= 
22 mice; α-CD8/α-NK1.1 + CD-HFD n= 8 mice). (j) NAS evaluation of mouse groups shown in h (H&E: ND n= 11 
mice; control CD-HFD n= 28 mice; α-CD8 + CD-HFD n= 23 mice; α-CD8/α-NK1.1 + CD-HFD n= 8 mice). All data 
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are shown as mean ± SEM. All data were analyzed by one way ANOVA and Tukey`s multiple comparison test, or 
two way ANOVA and Sidak`s multiple comparison test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
 
To decipher the mechanisms underlying increased liver damage and tumorigenesis as a result 
of α-PD-1 treatment in advanced stages of NASH pathology, I investigated cell types typically 
able to express PD-1 like CD4+ T-cells, NK and NKT cells, but also innate immune system 
cells potentially concerting cytotoxicity together with the CD8+ T-cell compartment. 
In both the main T-cell compartments, CD4+ as well as CD8+, GzmB expression was 
downregulated (Figure 23a). Upon α-PD-1 treatment less hepatic naïve CD4+ T-cells, but no 
significant enlargements of the memory effector and memory CD4+ T-cell compartments 
compared to CD-HFD control mice were detected (Figure 23b). Analysis of effector molecules 
of the CD4 lineage revealed only a significant difference in IL-10 expression (Figure 23c). 
Similar to the CD8 depletion experiment, I considered NK and NKT cells as potential mediators 
of liver damage. However, after analysis of three experimental cohorts, no difference in the 
numbers of NK or NKT cells for effector molecules could be detected (Figure 23d, e). In 
addition, the NKT type I to type II ratio was not significantly changed upon α-PD-1 treatment 
(Figure 23f). Analysis of innate immune cells expressing MHC II revealed more KC, mDCs 
and pDCs expressing MHC II upon α-PD-1 treatment (Figure 23f). 
Thus, I concluded, first that cytotoxic capacity by the GzmB axis decreases in the T-cell 
compartment after α-PD-1 treatment. Second, CD4+ T-cells are potentially more Th2 polarized, 
possibly as a means of coping with the increased liver damage through increased IL-10 
expression. Further, NK and NKT cells seem to play a minor role, but a strong activation of the 
innate immune cell compartment correlate with α-PD-1 treatment. 
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Figure 22: Blocking inhibitory PD-1/PD-L1 drives liver damage and tumorigenesis in advanced stages of 
NASH pathology 
(a) Body weight of 12 months ND, or CD-HFD fed mice, treated 2x per week for 8 weeks with IgG or α-PD-1 
antibodies (ND n= 8 mice; control CD-HFD n= 23 mice; α-PD-1 + CD-HFD n= 19 mice). (b) AST and ALT of mouse 
groups shown in a (ND n= 9 mice; control CD-HFD n= 31 mice; α-PD-1 + CD-HFD n= 17 mice). (c) IPGTT of mouse 
groups shown in a (control CD-HFD n= 8 mice; α-PD-1 + CD-HFD n= 10 mice). (d) H&E and Sirius Red staining 
with (e) NAS evaluation and Sirius Red quantification of mouse groups shown in a (H&E: ND n= 11 mice; control 
62 
CD-HFD n= 28 mice; α-PD-1 + CD-HFD n= 24 mice; Sirius Red: ND n= 12 mice; control CD-HFD n= 21 mice; α-
PD-1 + CD-HFD n= 18 mice). Scale bar: 50µm. (f) Tumor incidence of mouse groups shown in a (control CD-HFD 
n= 27 tumors in 74 mice; α-PD-1 + CD-HFD n= 16 tumors/lesions in 24 mice). (g) Absolute flow cytometric analysis 
of hepatic immune cells (control CD-HFD n= 10 mice; α-PD-1 + CD-HFD n= 13 mice). (h) Flow cytometric analysis 
of hepatic CD45+ cells (control + CD-HFD n= 11 mice; α-PD-1 + CD-HFD n= 13 mice). (i) Flow cytometric analysis 
for polarization of hepatic CD8+ T-cells (control + CD-HFD n= 11 mice; α-PD-1 + CD-HFD n= 13 mice). (j) Flow 
cytometric analysis for effector molecules of hepatic CD8+ T-cells (control + CD-HFD n= 11 mice; α-PD-1 + CD-
HFD n= 13 mice; for Prf: control + CD-HFD n= 4 mice; α-PD-1 + CD-HFD n= 4 mice). (k) Flow cytometric analysis 
of markers of hepatic T-cell exhaustion (control + CD-HFD n= 4 mice; α-PD-1 + CD-HFD n= 9 mice). (l) Flow 
cytometric analysis of FasL T-cell polarization (control + CD-HFD n= 4 mice; α-CD8 + CD-HFD n= 9 mice). All data 
are shown as mean ± SEM. All data were analyzed by one way ANOVA and Tukey`s multiple comparison test, or 
two way ANOVA and Sidak`s multiple comparison test, or for tumor incidence Fisher’s exact test. *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001. 
 
 
Figure 23: Deciphering tumor driving mechanism of PD-1 checkpoint blockade in advanced stages of NASH 
(a) Flow cytometric analysis for GzmB expression in hepatic CD3+ T-cells isolated from 12 months CD-HFD fed 
mice, treated 2x per week for 8 weeks with IgG or α-PD-1 antibodies (control + CD-HFD n= 8 mice; α-PD-1+ CD-
HFD n= 9 mice). (b) Flow cytometric analysis for polarization of hepatic CD4+ T-cells (control + CD-HFD n= 11 mice; 
α-PD-1+ CD-HFD n= 13 mice). (c) Flow cytometric analysis for effector molecules of hepatic CD4+ T-cells (control 
+ CD-HFD n= 8 mice; α-PD-1+ CD-HFD n= 13 mice). (d) Flow cytometric analysis for effector molecules of hepatic 
NK and (e) NKT cells (control + CD-HFD n= 4 mice; α-PD-1+ CD-HFD n= 9 mice; for perforin: control + CD-HFD 
n= 4 mice; α-PD-1+ CD-HFD n= 4 mice). (f) Flow cytometric analysis of hepatic NKT type I/II ratio (control + CD-
HFD n= 6 mice; α-PD-1+ CD-HFD n= 13 mice). (g) Flow cytometric analysis of hepatic innate immune system cells 
(KC: control + CD-HFD n= 6 mice; α-PD-1 + CD-HFD n= 4 mice; CD11b+: control + CD-HFD n= 10 mice; α-PD-1 + 
CD-HFD n= 13 mice; mDCs: control + CD-HFD n= 10 mice; α-PD-1 + CD-HFD n= 13 mice; pDCs: control + CD-
HFD n= 8 mice; α-PD-1 + CD-HFD n= 9 mice). All data are shown as mean ± SEM. All data were analyzed by two 
way ANOVA and Sidak`s multiple comparison test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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7.1.5 Deciphering mechanisms of immune cell mediated hepatocarcinogenesis 
To understand the tumor- and hepatic damage-promoting role of PD-1 blocking, I phenotyped 
the hepatic immune compartment in depth in collaboration with Nicolas Nunez and Burkhard 
Becher from the University of Zurich using a 24 multicolor flow cytometric analysis75.  
First, I defined in collaboration with Nicholas Nunez clusters of marker expression of living 
C45+ cells by t-distributed stochastic neighbor embedding (tSNE) analysis of randomly chosen 
5000 events of 12 month ND or CD-HFD with IgG, or α-CD8, or α-CD8/α-NK1.1 or α-PD-1 
treatment for 8 weeks (Figure 24a). By this approach, I in collaboration with Nicholas Nunez 
could define the hepatic immune compartment (B-cells, CD4+ or CD8+ or CD4-CD8- or 
regulatory T-cells, myeloid cells, NK cells and other leukocytes) (Figure 24b) and their 
frequency among CD45+ cells (Figure 24c). Further, I in collaboration with Nicholas Nunez 
assigned relative expression of markers to the individual populations of the defined hepatic 
immune cell compartment (Figure 24d). I found differences in the CD8+ T-cell compartment of 
12 month CD-HFD fed mice with IgG control treatment compared to α-PD-1 checkpoint 
inhibition. CD8+ T-cells increased in absolute numbers (mean difference -31; 95% CI -50 to -
13; p= 0.0007) and as a frequency of CD45+ cells (mean difference -9.07; 95% CI -14.27 to -
3.88; p= 0.0004).  
Thus, I focused on deciphering the effects of α-PD-1 treatment on TCRβ+ cells. After I defined 
clusters of marker expression of TCRβ+ cells in collaboration with Nicholas Nunez, tSNE 
analysis was performed on randomly chosen 5000 events among the treated groups described 
earlier (Figure 24e). I in collaboration with Nicholas Nunez assigned cells by tSNE analysis to 
different T-cell compartments (naïve or conventional CD4+; naïve or conventional CD8+; CD4-
CD8- T-cells and regulatory T-cells) (Figure 24f). Next, I in collaboration with Nicholas Nunez 
quantified the different T-cell compartments as frequency among CD45+ cells (Figure 24g). I 
in collaboration with Nicholas Nunez observed no differences in the CD4+ and regulatory T-
cell compartments between mice fed 12 months ND or CD-HFD treated with IgG or α-PD-1 in 
the frequency among CD45+ cells. However, I discovered differences in the conventional CD8+ 
T-cell and CD4-CD8- T-cell compartment between mice fed 12 months ND or CD-HFD treated 
with IgG in the frequency among CD45+ cells (conventional CD8+ T-cells: mean difference 21; 
95% CI -13 to 29; p< 0.0001 and CD4-CD8- T-cells: mean difference -11; 95% CI -19 to -3.1; 
p= 0.0049). Further, I saw trends for an decrease of conventional CD8+ T-cells in IgG control 
compared to α-PD-1 treated mice (mean difference -5.1; 95% CI -12 to 1.9; p= 0.1855).  
Therefore I decided to investigate the CD8+ T-cell compartment in more detail in order to 
decipher the reported immune-related adverse effects (irAEs), higher liver damage, and tumor 
formation after α-PD-1 treatment. 
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Figure 24: CD8 T-cells are the effector cells of immune-related adverse events upon PD-1 checkpoint 
blockade in advanced NASH 
(a) Unbiased analysis of 5000 randomly chosen events of a 24 color flow cytometric analysis to define distinct 
marker expression of mice 12 months fed ND or CD-HFD with IgG, or α-CD8, or α-CD8/α-NK1.1 or α-PD-1 
treatment for 8 weeks. (ND n= 4 mice; IgG + CD-HFD n= 8 mice; α-PD-1+ CD-HFD n= 6 mice; α-CD8 + CD-HFD 
n= 7 mice; α-CD8/α-NK1.1 + CD-HFD n= 7 mice). (b) Flowsom generated tSNE plots for definition of immune cell 
compartments of 12 months fed ND or CD-HFD with IgG or α-PD-1 treatment for 8 weeks. (c) Phenotypic 
composition of the immune cell compartment of individual mice shown in b (ND n= 4 mice; IgG + CD-HFD n= 8 
mice; α-PD-1+ CD-HFD n= 6 mice). (d) Heatmap of marker expression of immune cell populations defined in b. (e) 
Unbiased analysis of 5000 randomly chosen TCRβ+ cells of a 24 color flow cytometric analysis to define distinct 
marker expression of mice 12 months fed ND or CD-HFD with IgG, or α-CD8, or α-CD8/α-NK1.1 or α-PD-1 
treatment for 8 weeks. (ND n= 4 mice; IgG + CD-HFD n= 8 mice; α-PD-1+ CD-HFD n= 6 mice; α-CD8 + CD-HFD 
n= 7 mice; α-CD8/α-NK1.1 + CD-HFD n= 7 mice). (f) Flowsom generated tSNE plots for definition of TCRβ+ cell 
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compartments of 12 months fed ND or CD-HFD with IgG or α-PD-1 treatment for 8 weeks. (g) Phenotypic 
composition of the TCRβ+ cell compartment of individual mice shown in b (ND n= 4 mice; IgG + CD-HFD n= 8 mice; 
α-PD-1+ CD-HFD n= 6 mice). All data are shown as mean ± SEM. All data were analyzed by two way ANOVA and 
Dunnett`s multiple comparison test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
 
Next, I in collaboration with Nicholas Nunez defined clusters of marker expression for TCRβ+ 
CD8+ T-cells by tSNE analysis of randomly chosen 5000 events among the 12 month ND or 
CD-HFD treated with IgG as control or α-PD-1 for 8 weeks (Figure 25a). To identify subsets 
reactive to or changed upon α-PD-1 treatment, I in collaboration with Nicholas Nunez sub-
clustered the CD8+ T-cell compartment into 30 sub-clusters by tSNE analysis (Figure 25b) 
and quantified their abundance relative to CD45+ cells (Figure 25c). Cluster 3 (mean difference 
9.2; 95% CI 5.4 to 13; p= 0.0001) and Cluster 10 (mean difference -18; 95% CI -22 to -15; p= 
0.0001) were changed in CD-HFD fed mice treated with IgG compared to α-PD-1 treated mice. 
Next, I in collaboration with Nicholas Nunez assigned the relative expression of investigated 
molecules to the 30 individual clusters of the hepatic CD8+ T-cell compartment (Figure 25d). 
I in collaboration with Nicholas Nunez divided the 30 sub-clusters into two main populations, 
one associated with a memory phenotype including the decreased Cluster 3 upon α-PD-1 
treatment. The other main population was positive for TNF-a and PD-1, including Cluster 10, 
which was increased by α-PD-1 treatment (Figure 25e). Compared to IgG control, the TNF-
a+PD-1+ CD8+ T-cell population was increased (mean difference -23.5; 95% CI -46.82 to -0.19; 
p= 0.0482) upon α-PD-1 treatment (Figure 25f). Further, compared to the CD8+ memory T-
cell population, the TNF-a+PD-1+ CD8+ T-cell population expressed, in general, higher 
amounts of markers associated with activation (EOMES, Tbet), cytotoxicity (TNF-a, IFNy, 
GzmB) and exhaustion (PD-1, Tim-3) (Figure 25g). 
Further, in collaboration with Nicolas Nunez I applied a representation learning approach 
(CellCnn)77 to the flow cytometric data set. Using this method, I in collaboration with Nicholas 
Nunez could identify differential marker expression in the CD8+ T-cell compartment in a tSNE 
analysis (Figure 25h). Next, I in collaboration with Nicholas Nunez selected CD8+ T-cells 
negative for PD-1 and TNF-a (Figure 25i). Similar to Nicolas Nunez and my 30 sub-cluster 
approach (Figure 25a-f), I in collaboration with Nicholas Nunez determined that double-
negative PD-1-TNF-a- CD8+ T-cells were significantly increased in mice fed 12 months CD-
HFD and treated with IgG as a control compared to α-PD-1 treated animals (Figure 25j). 
Consequently, I confirmed by manual gating a significant increase of TNF-a+PD-1+ CD8+ T-
cells upon α-PD-1 treatment (Figure 25k, l).  
 
Of note, I did not observe an increase of TNF-a or PD-1 expression per CD8+ T-cell in a mean 
fluorescence based analysis, comparing IgG control with α-PD-1 treated animals. 
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Figure 25: PD-1+TNF-a+ CD8 T-cells are potential disease-driving effector cells upon PD-1 checkpoint 
blockade in advanced NASH 
(a) Unbiased analysis of 5000 randomly chosen TCRβ+ CD8+ cells of a 24 color flow cytometric analysis to define 
distinct marker expression of mice 12 months fed ND or CD-HFD with IgG, or α-CD8, or α-CD8/α-NK1.1 or α-PD-1 
treatment for 8 weeks. (ND n= 4 mice; IgG + CD-HFD n= 7 mice; α-PD-1+ CD-HFD n= 6 mice; α-CD8 + CD-HFD 
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n= 7 mice; α-CD8/α-NK1.1 + CD-HFD n= 7 mice). (b) Flowsom generated tSNE plots and unbiased clustering for 
30 clusters of 12 months fed ND or CD-HFD with IgG or α-PD-1 treatment for 8 weeks. (c) Phenotypic composition 
for the 30 clusters of individual mice defined in in b (ND n= 4 mice; IgG + CD-HFD n= 7 mice; α-PD-1+ CD-HFD n= 
6 mice). (d) Heatmap of marker expression and abundance relative to living CD45+ for the 30 clusters defined in b. 
(e) Flowsom generated tSNE plots for definition of CD8+ cell compartments (memory T-cells and TNF-a+PD-1+) of 
12 months fed CD-HFD with IgG or α-PD-1 treatment for 8 weeks. (f) Phenotypic composition of CD8+ T-cells (ND 
n= 4 mice; IgG + CD-HFD n= 7 mice; α-PD-1+ CD-HFD n= 6 mice). (g) Heatmap of marker expression of CD8+ T-
cells defined in e. (h) An unbiased analysis: CellCNN analysis of marker expression represented in tSNE plots of 
CD8+ T-cells of mice 12 months fed ND or CD-HFD with IgG, or α-CD8, or α-CD8/α-NK1.1 or α-PD-1 treatment for 
8 weeks. (ND n= 4 mice; IgG + CD-HFD n= 7 mice; α-PD-1+ CD-HFD n= 6 mice; α-CD8 + CD-HFD n= 7 mice; α-
CD8/α-NK1.1 + CD-HFD n= 7 mice). (i) CellCNN based analysis by tSNE of CD8+ T-cells for population selected 
for markers associated with no or low activation. (j) Quantification of population represented in i (IgG + CD-HFD n= 
5 mice; α-PD-1+ CD-HFD n= 4 mice). (j) Quantification by manual gaiting for PD-1+TNF-a+ CD8+ T-cells population 
for confirmation of defined population in i(IgG + CD-HFD n= 8 mice; α-PD-1+ CD-HFD n= 6 mice). (l) Representative 
flow cytometric plots of populations quantified in k. All data are shown as mean ± SEM. All data were analyzed two-
tailed Student T-test or Mann-Whitney. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
 
Thus, I concluded with three different approaches that hepatic irAEs in 12 month CDHFD 
treated with α-PD-1 are correlated with higher abundance and frequency of TNF-a+PD-1+ CD8+ 
T-cells. 
 
7.2 Aim 2: Platelet GPIbα is a mediator and potential interventional target for 
NASH and subsequent liver cancer 
7.2.1 New targets for breaking through the cycle of chronic hepatic inflammation in 
NASH 
After deciphering the role of T-cells in NASH and NASH induced hepatocarcinogenesis, I 
searched for an alternative way to target hepatic inflammation in NASH, without targeting 
potentially inflammation driving immune cell populations directly. Such an approach promised 
less adverse effects by not changing the immunological landscape drastically. Thus, it could 
unravel a more subtle manipulation of parameters responsible for NASH development, NASH 
pathology progression and subsequent tumor induction. 
Platelets were described in the literature as potential mediators of adverse effects in chronic 
liver inflammation, mainly in the background of chronic virus associated inflammation9,60–66. 
Further, previous work of Mohsen Malehmir in the group of Mathias Heikenwälder 
demonstrated that hepatic platelet numbers, as well as platelet aggregates are increased in 
CD-HFD induced NASH compared to healthy controls fed a normal chow diet59.  
As a follow up to this study, I investigated whether increased hepatic platelet numbers and 
aggregates are a result of hepatic steatosis and insulin resistance, resembling non-alcoholic 
fatty liver disease (NAFLD), or if hepatic inflammation resembling non-alcoholic steatohepatitis 
(NASH) is a key mediator driving hepatic platelet accumulation. 
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To this end, I fed WT mice either NAFLD-inducing diets, HFD-45% or a HFD with low sugar 
(HFD-60% + LS), and compared them to WT animals fed a NASH-inducing diets - choline 
deficient high fat diet (CD-HFD) or western-style diet with trans fats (WD-HTF). 
Adapted from my written and experimental contribution in Malehmir*, Pfister* et al.9: Wildtype 
(WT) mice fed for 6 months an NAFLD-inducing high fat diet (HFD-45%) developed 
macrovesicular steatosis by H&E and subsequently an increase in NAS, but no significant 
difference of hepatic platelet numbers (Figure 26a, b), despite significantly increased body 
weight compared to normal chow diet (ND) fed control mice (Figure 26c). To corroborate these 
results, I fed WT mice for 5 months a second NAFLD-inducing HFD with low sugar (HFD-60% 
+ LS). These HFD-60% + LS fed mice developed macrovesicular steatosis by H&E, 
subsequently an increase in NAS, but again no significant difference of hepatic platelet 
numbers (Figure 26d, e), despite significantly increased body weight and insulin resistance 
compared to ND fed control mice (Figure 26f, g). In contrast, WT mice fed 6 months an NASH-
inducing CD-HFD developed histopathological features of NASH (macrovesicular steatosis, 
hepatic immune cell infiltration and hepatocytic damage), together with a significant increase 
of hepatic platelet numbers compared to ND fed mice (Figure 26h, i). Mice fed WD-HTF 
developed similar to CD-HFD fed mice a phenotype of NASH and hepatic platelet accumulation 
compared to ND fed mice (Figure 26j, k). Further, in collaboration with Marco Prinz from the 
Universitätsklinikum Freiburg using electron microscopy I could demonstrate that platelets 
found in CD-HFD liver have an activated phenotype (Figure 26l) (adapted from Malehmir*, 
Pfister* et al.9). 
Thus, I concluded that increased hepatic platelet numbers and their activation status can only 
be found in livers of NASH-inducing diet-fed mice. Thus, antiplatelet treatment (APT) could be 
a therapeutic or interventional option for mice developing NASH. 
 
7.2.2 Therapeutic use of antiplatelet treatments in established NASH 
Mohsen Malehmir demonstrated that preventive use of APT like Aspirin-Clopidogrel (Asp-Clo), 
or Ticagrelor, but not the use of nonsteroidal anti-inflammatory drug (NSAID) Sulindac 
prevented NASH and subsequent HCC development59. Therefore, I investigated if not only the 
preventive but also the therapeutic use of APT in NASH could ameliorate NASH pathology. 
Adapted from my written and experimental contribution in Malehmir*, Pfister* et al.9: Therefore, 
WT mice fed 4 months of NASH-inducing diet were administered the platelet-specific APT 
Ticagrelor with continuous NASH diet for 2 months (Figure 27a). WT mice fed for 6 months 
CD-HFD with 2 months of Ticagrelor treatment had reduced hepatic platelet numbers and 
ameliorated NASH pathology by H&E compared to untreated CD-HFD fed mice (Figure 27b). 
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Therapeutic Ticagrelor treated mice were metabolically equally impaired by IPGTT, but had 
reduced ALT levels compared to untreated CD-HFD fed mice (Figure 27c). 
To corroborate these results, WT mice fed for 6 months WD-HTF with 2 months of Ticagrelor 
treatment also had reduced hepatic platelet numbers and a trend towards ameliorated NASH 
pathology by H&E compared to untreated WD-HTF fed mice (Figure 27d). Like CD-HFD fed 
mice, therapeutic Ticagrelor-treated WD-HTF fed mice were metabolically equally impaired by 
IPGTT but had reduced ALT levels compared to untreated WD-HTF fed mice (Figure 27e). In 
collaboration with Suchira Gallage, I investigated the effects of APT on fibrosis development. 
Therapeutic Ticagrelor-treated WD-HTF fed mice showed ameliorated fibrogenesis (Figure 
27f) (adapted from Malehmir*, Pfister* et al.9). 
Thus, I concluded that in established NASH pathology, APT using Ticagrelor can ameliorate 
NASH pathology or abrogate NASH progression in two murine models of NASH. 
 
7.2.3 Platelets - more than a bystander in NASH development 
Next, I investigated, when the platelets home to the liver upon NASH diet feeding and with 
which other cell type platelets co-localize indicating potential interaction with each other. 
Adapted from my written and experimental contribution in Malehmir*, Pfister* et al.9: In 
collaboration with Moritz Peiseler, Bas Surewaard and Paul Kubes from the University of 
Calgary I performed intravital microscopy to track intrahepatic platelets live in living mice, in 
order to understand the dynamics of intrahepatic platelet recruitment and platelet-cell 
interaction during the initial events of NAFL preceding NASH. Intravital microscopy of WT mice 
fed CD-HFD for 4, 5, 6 or 8 weeks showed, that platelets home the liver at this early time points 
of diet feeding in a progressive manner (Figure 28a, d), with no significant increase of hepatic 
CD3+ T-cells at this early time points (Figure 28b, c). Additionally, sinusoidal diameter is 
decreased (Figure 28e) and in collaboration with Suchira Gallage I showed, that hepatocytes 
start to increase in size at this early time points of CD-HFD feeding (Figure 28f). Further, 
pathological features of NASH start to develop (Figure 28g) and I observed a trend for an 
increase of hepatic triglycerides in CD-HFD fed mice (Figure 28h). 
I observed, in collaboration with Donato Inverso from the DKFZ Heidelberg using confocal 
microscopy, a significant increase of platelet aggregate size attached to Kupffer cell (KC) in 
established NASH (Figure 28i). Further, in collaboration with Moritz Peiseler, Bas Surewaard 
and Paul Kubes I found, that there is an induction of the extracellular matrix component 
hyaluronan colocalizing with hepatocytes, Kupffer cells and, to a lesser degree, on liver 
sinusoidal endothelial cells (LSECs) (Figure 28j) (adapted from Malehmir*, Pfister* et al.9). 
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Thus, I concluded, that platelets were the first non-resident cell type to home to the liver at 
earliest time points of borderline NASH development with sinusoidal diameter decrease and 
hepatocyte size increase. Further, my data indicated, that KCs and increased hyaluronan 
abundance may play key roles correlating with platelet attachment and recruitment in early 
phases NASH development9. 
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Figure 26: NASH diets induce hepatic platelet number and aggregation (adapted from Malehmir*, Pfister* et 
al.9) 
Adapted from my written contribution in Malehmir*, Pfister* et al.9: “(a) H&E, CD42b staining and (b) NAS evaluation 
and quantification of 6 months ND or HFD-45% fed mice (ND n= 6 mice; HFD-45% n= 7 mice). Scale bar: 50 µm. 
(c) Body weight (n= 6 mice/group) of mice shown in a. (d) H&E, CD42b staining and (e) NAS evaluation and 
quantification of 5 months ND or HFD-60%-fed (60% kcal and low sucrose (LS)) mice (ND n= 8 mice; HFD n= 6 
mice). (f) Body weight of mice shown in d (n= 7 mice/group). (g) Insulin tolerance test of mice shown in d (ND n=6 
mice; HFD-60%+LS n=7 mice). (h) H&E, CD42b staining and (i) NAS evaluation and quantification of 6 months ND 
or CD-HFD fed mice (NAS: ND n=15 mice; CD-HFD n=17 mice; CD42b: n= 7 mice/group). Scale bar: 50 µm. (j) 
H&E, CD42b staining and (k) NAS evaluation and quantification of 6 months ND or WD-HTF fed mice (NAS: n=5 
mice/group; CD42b: n= 6 mice/group). Scale bar: 50 µm. (l) Representative electron microscopy images of activated 
platelets in livers from 6 months ND or CD-HFD fed mice. (ND, left panel) Platelet adhering to an endothelial cell 
showing an inactivated appearance of tubular system, alpha granules, dense bodies and glycogen. (CD-HFD, right 
panel) Platelets close to fatty hepatocytes outside the vessels, showing signs of activation (compact dense 
granulae, closed canalicular system, enlarged size) (n= 4 mice/group). All data are represented as mean ± SEM. 
Data were analyzed by two way ANOVA and Sidak`s multiple comparison test or two-tailed Student T test. *: P < 
0.05. **: P < 0.01. ***: P < 0.001. ****: P < 0.0001”9. 
 
Although I did not find any increase of granulocytes or granulocyte-platelet interaction, 
literature indicated granulocytes as early responders of injury78. Therefore, in collaboration with 
Caroline L. Wilson, Jack Leslie and Derek A. Mann from Newcastle University I investigated 
the role of granulocytes using osmotic pumps for a constant depletion.  
Adapted from my written and experimental contribution in Malehmir*, Pfister* et al.9: WT mice 
fed 4 weeks CD-HFD were put under granulocyte depleting conditions with continuous NASH 
diet for 8 weeks (Figure 29a). Despite the granulocyte depletion being successful (Figure 
29b), no significant difference in body weight (Figure 29c), NASH pathology by H&E, hepatic 
platelet number (Figure 29d, e) or ALT levels was detected (Figure 29f) (adapted from 
Malehmir*, Pfister* et al.9). 
Thus, I concluded, that granulocytes played not a significant role in the CD-HFD model for 
early development of NASH pathology and borderline NASH. 
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Figure 27: Therapeutic anti-platelet treatment with Ticagrelor ameliorates NASH progression (adapted from 
Malehmir*, Pfister* et al.9) 
Adapted from my written contribution in Malehmir*, Pfister* et al.9: “(a) Experimental setup for therapeutic anti-
platelet treatments with Ticagrelor in 6 months ND, CD-HFD or WD-HTF fed mice. (b) H&E, CD42b staining and 
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(b) NAS evaluation and quantification of 6 months ND, CD-HFD or therapeutic CD-HFD/Ticagrelor fed mice (CD42b: 
ND n=8 mice; CD-HFD n=15 mice; CD-HFD/Ticagrelor n=8 mice; NAS: ND n=8 mice; CD-HFD n=7 mice; CD-
HFD/Ticagrelor n=8 mice). Scale bar: 50 µm. (c) IPGTT and ALT from mice shown in b (IPGTT: ND n=8 mice; CD-
HFD n=7 mice; CD-HFD/Ticagrelor n=8 mice; ALT: ND n=13 mice; CD-HFD n=13 mice; CD-HFD/Ticagrelor n=8 
mice). Statistics: ND vs CD-HFD (black asterisks), ND vs therapeutic CD-HFD/Ticagrelor (green asterisks). (d) 
H&E, CD42b staining and (b) NAS evaluation and quantification of 6 months ND, WD-HTF or therapeutic WD-
HTF/Ticagrelor fed mice (CD42b: n=9 mice/group; NAS: ND n=15 mice; WD-HTF n=16 mice; WD-HTF/Ticagrelor 
n=16 mice). Scale bar: 50 µm. (e) IPGTT and ALT from mice shown in d (IPGTT: n=8 mice/group; ALT: ND n=12 
mice; WD-HTF n=8 mice; WD-HTF/Ticagrelor n=7 mice). Statistics: ND vs WD-HTF (black asterisks), ND vs 
therapeutic WD-HTF /Ticagrelor (green asterisks). (f) Sirius Red staining and quantification of mice shown in d (ND 
n=8 mice; WD-HTF n=6 mice; WD-HTF/Ticagrelor n=6 mice). Scale bar: 50 µm. All data are shown as mean ± 
SEM. Data were analyzed by one way or two way ANOVA with Tukey’s or Sidak`s multiple comparison test.*: P < 
0.05. **: P < 0.01. ***: P < 0.001. ****: P < 0.0001” 9. 
 
7.2.4 Deciphering mechanisms of hepatic platelet homing in early NASH 
development  
After exclusion of a role of granulocytes in early time points of NASH development, I focused 
on the functional role of platelet-KCs and platelet-hyaluronan interactions to decipher 
mechanisms leading to platelet attachment and recruitment in early phases NASH 
development. 
Adapted from my written and experimental contribution in Malehmir*, Pfister* et al.9: WT mice 
fed 3.5 weeks CD-HFD were put under different treatment conditions with continuous CD-HFD 
diet for 2.5 weeks. Either I depleted KCs using clodronate liposome (CLL), I abrogated 
hyaluronan-platelet interaction using hyaluronidase (HYAL), or I treated with both together, 
CLL and HYAL. Further, hyaluronan can interact with CD44, which is highly expressed on 
platelets66. Thus, I investigated the role of CD44 binding using antibody mediated targeting of 
the CD44 binding sides, either with CD44/hyaluronan binding sides blocking (clone KM81) or 
non-blocking antibodies (clone IM7)66 (Figure 30a). 
In collaboration with Moritz Peiseler, Bas Surewaard and Paul Kubes from the University of 
Calgary I performed intravital microscopy to track the intrahepatic platelet response to the 
respective treatments. I successfully depleted KCs in mice treated with CLL (Figure 30b, c). 
6 weeks CD-HFD-fed mice with 2.5 weeks of treatment of either CLL or HYAL showed reduced 
NAS (Figure 30c) and reduced intrahepatic platelet abundance compared to control CD-HFD 
fed mice (Figure 30b, d). Mice treated with HYAL, but not CLL, had reduced ALT levels 
compared to untreated CD-HFD fed mice (Figure 30e). Combined treatment of HYAL and CLL 
did not further reduce intrahepatic platelet numbers compared to single treatments (Figure 
30f, g). Mice treated with α-CD44 binding/hyaluronan-blocking antibody (clone KM81), but not 
with α-CD44 binding/hyaluronan-non-blocking antibody (clone IM7) had reduced ALT levels 
(Figure 30h) and reduced NAS compared to untreated CD-HFD fed mice (Figure 30i, j). 
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Figure 28: Platelets home to the liver in early phases of NASH pathogenesis (adapted from Malehmir*, 
Pfister* et al.9) 
Adapted from my written contribution in Malehmir*, Pfister* et al.9: “(a) Intravital microscopy of livers of 4, 5, 6 and 
8 weeks ND or CD-HFD fed mice. Analysis of Kupffer cells (violet), platelets (blue) and granulocytes (red), (4 weeks: 
ND n= 2 mice; CD-HFD n= 2 mice; 5 weeks: ND n= 2 mice; CD-HFD n= 2 mice; 6 weeks: ND n= 4 mice; CD-HFD 
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n= 4 mice; 8 weeks: ND n= 3 mice; CD-HFD n= 3 mice). Scale bars: 40 µm. (b) CD3 staining and quantification of 
6 weeks (ND n= 4 mice; CD-HFD n= 8 mice) or (c) 8-weeks ND or CD-HFD fed mice (ND n= 5 mice; CD-HFD n= 
4 mice). Scale bar: 50 µm. (d) Quantification of platelet area by intravital microscopy of mice shown in a (ND: 4 
weeks n= 2 mice and 40 FOV; 5 weeks n= 2 mice and 40 FOV; 6 weeks n= 4 mice and 40 FOV; 8 weeks n= 2 mice 
and 40 FOV; CD-HFD: 4 weeks n= 2 mice and 20 FOV; 5 weeks n= 2 mice and 20 FOV; 6 weeks n= 4 mice and 
30 FOV; 8 weeks n= 2 mice and 19 FOV). (e) Analysis of liver sinusoid diameter by intravital microscopy of mice 
shown in a (ND: 4 weeks n= 2 mice and 101 sinusoids; 5 weeks n= 2 mice and 150 sinusoids; 6 weeks n= 4 mice 
and 100 sinusoids; 8 weeks n= 2 mice and 150 sinusoids; CD-HFD: 4 weeks n= 2 mice and 100 sinusoids; 5 weeks 
n= 2 mice and 150 sinusoids; 6 weeks n= 4 mice and 100 sinusoids; 8 weeks n= 2 mice and 100 sinusoids). (f) 
Hepatocyte swelling measurement by H&E of mice shown in b and c (6 weeks: ND n= 4 mice; CD-HFD n= 3 mice; 
8 weeks: ND n= 3 mice; CD-HFD n= 4 mice). Scale bar: 50 µm. (g) NAS evaluation of 6 or 8 weeks ND- or CD-
HFD fed mice (6 weeks: ND n= 19 mice; CD-HFD n= 18 mice; 8 weeks: ND n= 3 mice; CD-HFD n= 6 mice). (h) 
Liver triglycerides of 6 weeks ND or CD-HFD fed mice (n= 3 mice/group). (i) 3D confocal images and quantification 
of platelet (green)/Kupffer cells (red) interaction of 6 months ND or CD-HFD fed mice (n= 4 mice/group). Liver 
endothelium (gray). Scale bar: 20 µm. (j) Left, representative images of intravital microscopy of 6 weeks ND or CD-
HFD fed mice. Right, representative high-magnification images of intravital microscopy. Analysis of Kupffer cells 
(violet, violet arrowhead), HABP (red, red arrowhead) and LSECs (blue) (ND n= 4 mice; CD-HFD n= 4 mice). Scale 
bar: 43 µm. All data are shown as mean ± SEM. All data were analyzed using two-tailed Student T test. *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001”9. 
 
Further, in mice with established NASH fed 6 months CD-HFD a short treatment of CLL for 2.5 
weeks led to a significant reduction of NAS and platelet accumulation (Figure 30k, l) (adapted 
from Malehmir*, Pfister* et al.9). 
Thus, I concluded that KC, hyaluronan and CD44 are important players in the early and 
advanced stages of NASH development and NASH progression9. 
 
Adapted from my written and experimental contribution in Malehmir*, Pfister* et al.9: To 
corroborate my findings in the CD-HFD model with a second model of NASH, I fed WT mice 
3.5 weeks WD-HTF and depleted KCs using CLL with continuous WD-HTF diet for 2.5 weeks 
(Figure 31a).  
In collaboration with Moritz Peiseler, Bas Surewaard and Paul Kubes from the University of 
Calgary I performed intravital microscopy of 6 or 8 weeks ND or WD-HTF fed mice (Figure 
31b). I corroborated my results from the CD-HFD model with respect to increased and 
progressive hepatic platelet abundance (Figure 31b, c) in borderline NASH by H&E (Figure 
31d, e) and increased hepatic liver triglycerides (Figure 31f) in 6 or 8 weeks WD-HTF fed mice 
compared to ND fed mice (adapted from Malehmir*, Pfister* et al.9). 
Thus, I concluded that similar to the CD-HFD model, platelets were the first non-resident cell 
type to home to the liver at earliest time points of borderline NASH in the WD-HTF model. 
Further, my data indicated that KCs may play key roles correlating with platelet attachment 
and recruitment in early phases NASH development in the WD-HTF model9. 
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Figure 29: Granulocyte abundance does not delay NASH development (adapted from Malehmir*, Pfister* et 
al.9) 
Adapted from my written contribution in Malehmir*, Pfister* et al.9: “(a) Experimental setup for α-Ly6G depletion in 
12 weeks ND or CD-HFD fed mice. (b) Myeloperoxidase (MPO) of 12 weeks CD-HFD + IgG or CD-HFD + α-Ly6G 
fed mice (n=4 mice/group). Scale bar: 50 µm. (c) Body weight, (d) H&E, CD42b staining, (e) NAS evaluation and 
quantification and (f) ALT of mice shown in b (body weight and ALT: n=5 mice/group; CD42b: CD-HFD + IgG n=4 
mice, CD-HFD + α-Ly6G n=4 mice; NAS: CD-HFD +IgG n=4 mice, CD- HFD +α-Ly6G n=5 mice). Scale bar: 50 µm. 
All data are shown as mean ± SEM and were analyzed using two-tailed Student T test. *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001”9. 
 
7.2.4 GPIbα – an interventional target on platelets for amelioration of NASH pathology 
and NASH induced hepatocarcigonesis  
Adapted from my written and experimental contribution in Malehmir*, Pfister* et al.9: My data 
indicated that intrahepatic interaction of platelets with KCs, involving hyaluronan/CD44 binding, 
contributed to NASH development and progression. Further, previous work of Mohsen 
Malehmir from the group of Mathias Heikenwälder demonstrated by using different genetic 
mouse model under CD-HFD, that platelet cargo (Nbeal2-/-) but not platelet aggregation 
(Itga2b-/-), nor specific platelet activation (GPVI-/-) is important to abrogate or ameliorate NASH 
pathology59.  
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Figure 30: Intrahepatic platelet accumulation depends on Kupffer cells and CD44-hyaluronan interaction in 
early phases of NASH pathogenesis (adapted from Malehmir*, Pfister* et al.9) 
Adapted from my written contribution in Malehmir*, Pfister* et al.9: “(a) Experimental setup for various treatments 
(clodronate liposome (CLL), hyaluronidase (HYAL) or both (HYAL+CLL), or α-CD44 antibodies) in 6 weeks ND or 
CD-HFD. (b) Representative images of intravital microscopy after treatment (CLL or HYAL) of 6 weeks ND, CD-
HFD, CD-HFD + CLL or CD-HFD + HYAL fed mice. Analysis of Kupffer cells (violet), platelets (blue, blue arrowhead) 
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and granulocytes (red) (n= 4 mice/group). Scale bar: 40 μm. (c) H&E and F4/80 staining with quantification and 
NAS evaluation of 6 week ND, CD-HFD, CD-HFD + CLL or CD-HFD + HYAL fed mice (H&E: ND n= 10 mice; CD-
HFD n= 14 mice; CD-HFD + CLL n= 9 mice; CD-HFD + HYAL n= 8 mice; F4/80: ND n= 7 mice; CD-HFD n= 10 
mice; CD-HFD + CLL n= 4 mice; CD-HFD + HYAL n= 5 mice). Scale bar: 50 µm. (d) Quantification of platelet area 
by intravital microscopy of mice shown in b (ND n= 4 mice and 40 FOV; CD-HFD n= 4 mice and 30 FOV; CD-HFD 
+ CLL n= 4 mice and 40 FOV; CD-HFD + HYAL n= 4 mice and 30 FOV). (e) ALT levels of mice shown in b (ND n= 
17 mice; CD-HFD n= 13; CD-HFD + CLL n= 7 mice; CD-HFD + HYAL n= 8 mice). (f) CD42b quantification and (g) 
CD42b staining of 6 weeks ND, CD-HFD, CD-HFD + CLL or CD-HFD + CLL/HYAL fed mice (ND n=9 mice, CD-
HFD n=9, CD-HFD+CLL and CD-HFD+CLL/HYAL n=5 mice/group). Scale bar: 50 µm. (h) ALT, (i) H&E and (j) NAS 
evaluation after anti-CD44 antibody treatment (anti-CD44 antibody blocking (KM81) or non-blocking (IM7) HA-
binding site) in 6 weeks ND, CD-HFD, CD- HFD + IM7 (non-HA blocking) or CD-HFD + KM81 (HA-blocking) fed 
mice (ALT: ND n= 16 mice; CD-HFD n= 12 mice; CD-HFD + IM7 n= 4 mice; CD- HFD + KM81 n= 4 mice; NAS: ND 
n= 19 mice; CD-HFD n= 15 mice; CD-HFD + IM7 n= 4 mice; CD-HFD + KM81 n= 4 mice). Scale bar: 50 µm. (k) 
H&E, CD42b staining and (l) NAS evaluation and quantification after CLL treatment in 6-months CD-HFD or CD- 
HFD + CLL fed mice (NAS: CD-HFD n= 5 mice; CD-HFD + CLL n= 3 mice; CD42b: CD-HFD n= 5 mice; CD-HFD 
+ CLL n= 3). Scale bars: 50 µm. All data are shown as mean ± SEM. All data were analyzed using one way ANOVA 
with Tukey’s multiple comparison test or two-tailed Student T test.*: P < 0.05. **: P < 0.01. ***: P < 0.001. ****: P < 
0.0001”9. 
 
However, Mohsen Malehmir`s work and literature indicated that GPIbα on platelets is important 
for platelet attachment, as well as activation and thus potentially for NASH development59,60. 
Therefore, in collaboration with Donato Inverso from the DKFZ, Heidelberg, using confocal 
microscopy I showed that in 6 months CD-HFD fed mice increased amounts of GPIbα+ 
platelets colocalized with KCs and decreased amounts of GPIbα+ platelets with LSECs 
compared to ND fed mice (Figure 32a, b). Therefore, I treated 6 months CD-HFD fed mice 
with established NASH therapeutically using GPIbα blocking Fab fragments for 5 weeks. After 
5 weeks of GPIbα blocking treatment with continuous CD-HFD diet, the mice had ameliorated 
NASH pathology by H&E, reduced intrahepatic platelet numbers (Figure 32c), less liver 
damage (Figure 32d) and reduced hepatic liver triglycerides (Figure 32e). Further, in 
collaboration with Suchira Gallage I observed a trend for ameliorated fibrosis (Figure 32f, g). 
Of note, in anti-GPIbα-treated mice, intrahepatic CD3 T-cell and KCs levels remained 
unchanged (Figure 32h, i). 
Next, in collaboration with Moritz Peiseler, Bas Surewaard and Paul Kubes from the University 
of Calgary I tested whether blocking GPIbα in early NASH development would have an effect. 
Thus, mice fed 6 weeks CD-HFD with 2.5 weeks of GPIbα blocking antibody were analyzed 
by intravital microscopy. However, no differences in intrahepatic platelet abundance could be 
observed (Figure 32j). 
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Figure 31: Corroboration of platelet phenotype with a second model of NASH diet (adapted from Malehmir*, 
Pfister* et al.9) 
Adapted from my written contribution in Malehmir*, Pfister* et al.9: “(a) Experimental setup for CLL treatment in 6 
weeks ND or WD-HTF fed mice. (b) Intravital microscopy of livers of 6 and 8 weeks ND or WD-HTF fed mice. 
Analysis of Kupffer cells (violet), platelets (blue) and granulocytes (red) (n=4 mice/group), scale bar: 40 µm. (c) 
Quantification of platelet area by intravital microscopy of mice shown in b (n=4 mice/group). (d) NAS evaluation by 
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(e) H&E staining of mice shown in b (6 weeks: ND n=19 mice, WD-HTF n=10 mice; 8 weeks: n=3 mice/group). (f) 
Liver triglycerides of 6 weeks fed ND or WD-HTF mice (n=4 mice/group). (g) H&E, CD42b, F4/80 staining, 
quantification and NAS evaluation (NAS: ND n=6 mice, WD-HTF n=5 mice/group; WD-HTF + CLL n=5 mice/group; 
CD42b: ND n=10 mice, WD-HTF n=5 mice/group; WD-HTF + CLL n=5 mice/group) and (h) ALT levels in 6 weeks 
fed ND or WD-HTF mice (ND n=10 mice, WD-HTF, n=8 mice WD-HTF+CLL n=4 mice). Scale bar: 50 µm. All data 
are shown as mean ± SEM. Data were analyzed using two-tailed Student T test or one way ANOVA with Tukey`s 
multiple comparison test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001”9. 
 
Previous work by Mohsen Malehmir from the group of Mathias Heikenwälder demonstrated 
that mice with a ligand-binding ectodomain of GPIbα replacement by the α-subunit of the 
human IL-4 receptor (hIL4rα/GPIbα-Tg)79 were protected from NASH pathology upon 6 months 
of CD-HFD feeding9,59. As a follow up, I investigated whether hIL4rα/GPIbα-Tg, despite being 
protected from NASH after 6 months of CD-HFD feeding, would develop tumors after 12 
months of CD-HFD feeding. 12 months CD-HFD fed hIL4rα/GPIbα-Tg mice had reduced liver 
damage (Figure 32k) and no macroscopic (Figure 32l) or microscopic tumor development 
(Figure 32m), resulting to a significantly reduced tumor burden compared to CD-HFD fed WT 
mice (Figure 32n) (adapted from Malehmir*, Pfister* et al.9). 
Thus, I concluded that GPIbα on platelet is a mediator of platelet-KC interaction, a potential 
interventional target for NASH by Fab-mediated GPIbα blocking and therefore a potential 
target reducing NASH induced hepatocarcinogenesis. 
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Figure 32: Antibody mediated blockade of GPIbα ameliorates established NASH pathology, but not NASH 
development and dysfunctional GPIbα abrogates hepatocarcinogenesis (adapted from Malehmir*, Pfister* 
et al.9) 
Adapted from my written contribution in Malehmir*, Pfister* et al.9: “(a) 3D confocal images of GPIbα (green) and 
Kupffer cells (red) interaction of 6 months ND or CD-HFD fed mice (n= 4 mice/group). Liver endothelium (gray). 
Scale bar: 30 µm. (b) High-magnification 3D confocal images and quantification of GPIbα (green)/Kupffer cells (red) 
and GPIbα (green)/LSECs (gray) interaction in 6 months ND or CD-HFD fed mice (ND n= 4 mice and 2 FOV/mouse; 
CD-HFD n= 4 mice and 2 FOV/mouse). Scale bar: 3 µm. For visualization of intravascular events, the transparency 
of the sinusoidal rendering was set to 50%. (c) H&E, CD42b staining, NAS evaluation and quantification after 5 
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weeks of GPIbα blocking or control antibody (ab) in 6 months CD-HFD fed mice (CD42b: CD-HFD + control ab n= 
8 mice; CD-HFD + GPIbα blocking ab n= 8 mice; NAS: CD-HFD + control ab n= 5 mice; CD-HFD + GPIbα blocking 
ab n= 4 mice) Scale bar: 50 µm. Platelet aggregates are indicated by arrows. (d) ALT, (e) liver triglycerides, (f) 
quantification of (g) Sirius red–positive areas of mice shown in c (ALT: CD-HFD + control ab n= 5 mice; CD-HFD + 
GPIbα blocking ab n= 4 mice; liver triglycerides: CD-HFD + control ab n= 4 mice; CD-HFD + GPIbα blocking ab n= 
4 mice; Sirius red: CD-HFD + control ab n= 5 mice; CD-HFD + GPIbα blocking ab n= 4 mice). Scale bar: 50 µm. (h) 
CD3, F4/80 staining and (i) quantification of mice shown in c (n= 5 mice/group). Scale bar: 50 µm. (j) Intravital 
microscopy of Kupffer cells (violet), granulocytes (red), platelets (blue) and quantification of platelet area per FOV 
of livers of 2.5 weeks treatment in 6 weeks ND, CD-HFD + ctrl ab or CD-HFD +GPIbα blocking antibody fed mice 
(FOV n=5 fields/mouse, ND n= 8 mice, CD-HFD n= 6 mice, CD-HFD + GPIbα blocking antibody n= 4 mice), scale 
bar: 40 µm. (k) ALT of 12 months ND, CD-HFD or CD-HFD/hIL4rα/GPIbα-Tg mice (ND n= 12 mice; CD-HFD n= 16 
mice; CD-HFD/hIL4rα/GPIbα-Tg n= 9 mice). (l) Macroscopical images of tumors of mice shown in k; tumor nodules 
are indicated by arrowhead) (CD-HFD: n= 13 tumors in 52 mice; CD-HFD/hIL4rα/GPIbα-Tg: n= 0 tumors in 24 
mice). Scale bar: 750 µm. (m) Tumor characterization by CD44v6, Collagen IV (Coll IV) and Ki67 staining of mice 
shown in k. Arrowheads indicate positive hepatocytes, dashed line indicates tumor (T) border. Scale bar: 200 µm 
(CD44v6 and Coll IV), 50 µm (Ki67). (n) Tumor incidence (T = tumor; NT = non-tumor) of 12 months CD-HFD-fed 
or CD-HFD/hIL4rα/GPIbα-Tg mice (CD-HFD: n= 13 tumors in 52 mice; CD-HFD/hIL4rα/GPIbα-Tg: n= 0 tumors in 
24 mice). All data are shown as mean ± SEM. Data were analyzed using two-tailed Student T test, one way ANOVA 
with Tukey`s multiple comparison test or Fisher’s exact test. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001”9. 
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8 Discussion 
 
8.1 Aim 1: Deciphering TCR signaling in metabolically activated T-cells in 
NASH and liver cancer development 
In the frame of this PhD thesis, I report several findings that help decipher the role of TCR-
dependent cell-mediated mechanisms driving liver pathogenesis in metabolic disease, NAFLD, 
NASH and dietary-induced tumor burden.  
I identified that only NASH-inducing CD-HFD, but not NAFLD-inducing HFD, led to liver 
damage in systemically obese mice, which correlated with an increase of activated and 
memory CD8+ T-cells positive for IFNy and PD-1 - an effect, which increased over time and 
thus correlated with progression of disease. Further, these effects were corroborated using a 
second model of mouse NASH, WD-HTF. Over the past decade, a variety of metabolic disease 
models recapitulating to different degrees NAFLD or NASH with or without tumor induction 
have been published40. In line with recent models of not only NAFLD but NASH, I could identify 
a hepatic T-cell phenotype in the CD-HFD model, as well as a WD-HTF-based 
model6,31,33,46,47,51. Unfortunately, relating these results to two relatively recent publications is 
difficult, because the studies utilizing the genetic model of c-myc overexpression plus 
methionine-choline deficient diet (MCD), as well as a genetic model with inducible human URI 
reported data focused on intrahepatic CD4+ T-cells, without considering in depth the potential 
role of the CD8 compartment31,46. Of note, the role of the CD4+ compartment is important, 
especially differential polarization of these cells, like the Th17 compartment, as well as the 
selective loss of regulatory CD4+ T-cells in driving pathologies resembling NASH80. 
Nevertheless, in a model of hepatocellular damage combined with HFD and DEN injection, 
Shalapour et al. reported comparable results to my observed phenotypes of hepatic immune 
cell abundance and density, CD45 polarization, activation and effector molecule expression in 
the CD8+ T-cell compartment51. Further, studies in patients have linked inflamed livers with 
increased peripheral IFNy+ CD8+ T-cells, as well as higher hepatic infiltration and increased 
production of IFNy by these cells in NASH81,82. In addition, obesity was linked with PD-1 
expressing CD8+ T-cells in mice, macaques and human83.  
Next, I found, that progression of NASH disease is correlated with differential TCR vβ hepatic 
expression in PD-1+CD8 T-cells, as well as a dependency for NASH development on a natural 
TCR repertoire and a functional TCR effector function, but not NKT type I or type II cells. 
Studies about hepatic TCR repertoires are scarce, with most of the studies focusing on adipose 
tissue T-cells. In these studies, activated CD8+ T-cells together with reduced regulatory T-cells 
contribute to inflammatory macrophage influx, insulin resistance and glucose intolerance in 
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models of NAFLD84–86. However, similar to my results showing that the hepatic TCR repertoire 
of the whole population of hepatic CD4+ and CD8+ T-cells between ND and CD-HFD is not 
changed, a study by McDonnell et al. reported no significant change of hepatic CD8+ T-cell 
clonality by deep sequencing of the TCRβ chains in an NAFLD model87. However, referring to 
the differences I observed in my comparison between NAFLD- and NASH-inducing diets (e.g. 
activation and expression of exhaustion marker of CD8+ T-cells, increased ALT levels), the 
inflammatory part in the liver is strongly reduced or might not be present in these models of 
NAFLD. Other NASH studies in the context of tumor development need to be scrutinized, 
because they might overlook TCR repertoire changes induced by NASH pathology, due to 
potential strong reactions against tumor-associated antigens that might mask NASH-
associated TCR repertoires. Future single-cell RNA sequencing-based approaches combined 
with flow cytometric analysis could pave the way for a more in-depth understanding of NASH-
induced TCR repertoire changes. To the best of my knowledge, no study has thus far reported 
TCR repertoires which could explain my observed changes of the hepatic PD-1+ expressing 
T-cells, which could drive liver inflammation in a oligo-clonal manner in the context of 
progressing NASH pathology. 
In line with my results that there is a need for functional TCRs for NASH development, as well 
as a natural TCR repertoire, studies addressed NAFLD or NASH development in TCR-deficient 
mice (e.g. Rag-1-/-, nude mice, β2m-/-) and concluded that there was a lack of hepatic fat 
deposition, as well as, depending on the study, glucose intolerance6,88. Further, an impaired 
CD8 compartment led to decreased liver damage in an HFD ischemia reperfusion model89. 
These data indicate a mostly TCRαβ dependency for NASH development; however, the exact 
role of TCRγδ is so far not well-characterized and should be characterized in greater detail90,91. 
The use of single knockouts for TCRβ and TCRδ under NASH-inducing diets could shed new 
light on this issue.  
Additionally, active and functional TCR effector function is important for driving NASH 
pathology, either directly by TCR MHC interaction or by similar mechanisms. Mauro et al. 
reported a mechanism of PI3K activation of CD4+ T-cells by palmitate on the background of a 
HFD, which could potentially activate CD8+ T-cells in a similar fashion92. In contrast to Revelo 
et al. using Prf1-/- under HFD and therefore NAFLD conditions, Prf1-/- under long-term CD-HFD 
performed significantly better in glucose tolerance test and had ameliorated liver pathology93. 
However, lack of perforin in my hands could only delay but not abrogate NASH pathology and 
subsequent tumor development, shedding new light on the role of perforin dependency in 
NASH. Potentially, secondary mechanisms besides T-cell activation may drive liver disease 
progression. In line, the study of Revelo et al. reported higher levels of IFNy-producing CD8+ 
T-cells in adipose tissue in Prf1-/- mice, leading to higher fat tissue inflammation, adipose tissue 
fibrosis and a potential feedback loop to the liver, inducing steatosis and insulin resistance94. 
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Another potential side effect of using global perforin knockout mice is a reduction of perforin-
positive dendritic cells, a regulatory DC compartment associated with protection from 
metabolic syndrome and autoimmunity95. To this end, the use of specifically TCR signaling 
impaired mice (e.g. conditional SLP76 knockout) or mice with perforin knockouts in specific 
cell types, rather than the whole-body TCR effector impaired Prf1-/- could shed new light on the 
specific TCR dependency in NASH development. One remaining question is still unanswered. 
What activates the T-cells in the first place, and is it antigen-dependent (e.g. classical versus 
non-classical antigen presentation) or antigen-independent (e.g. metabolic or cytokine 
microenvironment)? 
NKT cells are widely accepted to play an important role in energy, adipose tissue homeostasis 
and liver homeostasis, although their precise role in an organ-related context is highly 
variable6,36,96–98. Further, NKT cells could play an important role in my Prf1-/- CD-HFD mice. 
However, I could only observe an increased glucose tolerance after 6 months of CD-HFD 
feeding, indicating a potential role of NKT cells in adipose tissue. In line, Lynch et al. reported 
that activation of adipose-resident NKT cells increased, in an FGF21-dependent manner, 
thermogenesis by browning of white adipose tissue96. One of my most robust findings is that 
no matter which animal model was put under NASH-inducing dietary conditions, after 
developing NASH, the NKT type I to type II ratio was always shifted to more type II NKT cells. 
This indicates that, on the one hand, there could be a selective loss of NKT type I99, which 
could potentially on its own lead to hepatic steatosis and insulin resistance100. On the other 
hand, I observed an increase in type II NKT cells, which could be either driving the pathology 
or promoting hepatocarcinogenesis by promoting a Th2-polarized hepatic environment. 
Nevertheless, the role of NKT type I and type II could not be conclusively deciphered in the 
frame of this thesis - also with respect to the newly described innate lymphoid cells. One 
potential approach to define the role of NKT cells in NASH further could be either the activation 
of the NKT compartment by a-Gal treatment or a genetic increase of this compartment using 
CD4-Cre Vα14iStopF/wt 101. However, the majority of non-significant differences between Jα18-/- 
or CD1d-/- with their respective control mice under CD-HFD, indicated a minor contribution of 
these cells in the investigated time points of NASH and advanced NASH states in the used 
NASH mouse model98,102. 
Thus, I focused on CD8-mediated mechanism in early NAFLD to NASH progression, as well 
as advanced NASH stages by antibody-mediated CD8 depletion and PD-1 blocking 
experiments. I reported a contribution of CD8+ and PD-1-expressing cells depending on NASH 
pathology progression. When CD8+ T-cells get depleted in established NASH, two studies 
report beneficial effects by reduced ALT, reduced liver triglycerides, reduced mRNA levels α-
smooth muscle actin and collagen type 1 expression, as well as improved NAS6,33. Therefore, 
there are strong indications, that adaptive immune cells, especially CD8+ T-cells in concert with 
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NKT, drive NAFLD development and NASH progression103. However, my CD8 depletion data 
from 4 to 6 months before manifestation of NASH, indicated, that probably subsets of the 
IFNy+CD8+ T-cells have not only a damage driving, but a protective role as well. Ablation of 
CD8+ T-cells in the genetic MUP-uPA and the MCD mouse model indicated an anti-fibrotic role 
of CD8+ correlating with IFNy levels as well35. Further, unpublished data from my collaborator 
indicated increased ALT because of CD8 depletion, too. If this increased damage upon CD8 
depletion is a result of hepatic or peripheral mechanisms (e.g. adipose tissue inflammation, or 
loss of CD8+ T-cell dependent intestinal barrier integrity104,105), remains up to date illusive. 
However, upon CD8 depletion in advanced stages of NASH, I see less tumor burden, indicating 
CD8+ T-cells drive liver pathology after NASH is established, similar to reports of Wolf et al. 
and Bhattacharjee et al., which both identified CD8+ T-cells as drivers of liver damage6,33. To 
date, I have not identified a clear mechanism, by which ALT as a marker of liver damage is 
elevated in my CD8-depleted animals. I did not observe compensatory effects in the innate 
immune system, CD4+ T-cell, NK or NKT compartment by flow cytometric phenotyping. In 
addition, double depletion of NK1.1 and CD8 T-cells did not result in lower liver damage or 
reduced NASH pathology, indicating a more complex driver of hepatic damage in advanced 
NASH. Potential mechanism could be increased levels of TNF-a37, IL-1β106, IL-6107, IL-1746 or 
metabolite-mediated lipotoxicity31. Further, potential dual roles of cytokines as either tumor-
counteracting or tumor-promoting need to be analysed, for example IL-12, IFNy, high levels of 
GzmB, lymphotoxin α and β, as well as molecules of the M2 polarization like IL-10 and TGF-
β3. Hepatocyte-intrinsic metabolic toxicity, ER stress and reactive oxygen species could also 
be responsible for the elevated ALT levels upon CD8 depletion in advanced NASH. 
Nevertheless, when increasing the activity of PD-1-expressing cells in advanced NASH by 
clinically used doses of α-PD-1 blockade108, I observed a significant increase in liver damage, 
liver pathology and tumor/nodule/lesion formation. Similar to my CD8 depletion experiments, 
the mechanisms promoting the observed liver damage and subsequent tumor/nodule/lesion 
formation have thus far been elusive. Similar to the CD8 depletion experiments, I observed no 
significant changes of damage-promoting or activation-associated mechanisms in the CD4+ T-
cell, NK or NKT compartment by flow cytometric phenotyping. This indicated α-PD-1-reactive 
CD8+ T-cells and cells of the innate immune system are the main drivers of liver damage upon 
checkpoint inhibition. However, in-depth histopathological evaluation of the immune-related 
adverse events (irAEs) upon α-PD-1 treatment combined with in-depth characterization of the 
immune compartment by single cell RNA sequencing approaches could help to decipher my 
observed irAEs in more detail. 
So far, the application of checkpoint inhibitiors (clinically used α-PD-1 inhibitors Nivolumab and 
Pembrolizumab) in hepatocellular carcinoma has been considered safe in clinical phase I/II109 
and II110 studies. However, in general, 1-4% of patients receiving Nivolumab as anti-cancer 
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therapy developed hepatitis111. With the increasing number of studies using next generation 
checkpoint inhibitors (e.g. 34 studies with Nivolumab and status “active” or “recruiting”112; or 
29 studies with Pembrolizumab and status “active” or “recruiting”113), it is of great importance 
for clinical management to understand the checkpoint inhibition-induced hepatotoxicity and 
irAEs114–116. For example, a study of mainly melanoma patients treated with Nivolumab (α-PD-
1) or Ipilimumab (α-CTLA-4) reported irAEs by comparing checkpoint inhibitor induced 
hepatitis with drug-induced or autoimmune hepatitis117. Zen et al. reported that, as a result of 
checkpoint inhibitor treatment, higher numbers of liver-infiltrating CD8+ T-cell were found 
without markers of classical autoimmune hepatitis, like zonal necrosis, anti-nuclear antibodies 
and elevated IgG levels117. However, irAEs can be even more severe. For example, a case 
study of a hepatitis virus-negative patient with advanced HCC plus bilateral pulmonary 
metastases who was unresponsive to first-line treatment with Sorafenib demonstrated that 
administration of Pembrolizumab led to acute liver failure and subsequent death118. 
As a consequence, in clinical practice, corticosteroids are recommended for treatment of irAEs 
induced by checkpoint inhibition114. However prolonged or high-dose corticosteroid therapy is 
known to induce hepatic steatosis, increased ALT and a liver pathology similar to NASH119. 
Thus, corticosteroid therapy for irAEs resulting from checkpoint inhibition as treatment of 
NASH-induced tumors could be detrimental120. Postow and Wolchok suggest TNF-a inhibitor 
Infliximab as a potential management option for irAEs in patients without elevated ALT 
levels114. TNF-a inhibiting agents like Infliximab have, on the one hand, been reported to cause 
hepatotoxicity and worsening of autoimmune-modulatory phenotypes121 and, on the other 
hand, also to reduce steatosis and increase insulin signal transduction in animal models122. My 
CD8 depletion data implicating CD8 T-cells as the main drivers of disease with subsequent 
tumor development. Further, my unbiased analysis of our flow cytometric data set in which I in 
collaboration with Nicholas Nunez identified significantly enriched hepatic PD-1+TNF-a+ CD8+ 
T-cells indicate that TNF-a inhibitors, like Infliximab, could potentially help to reduce irAEs upon 
checkpoint inhibition in the case of an underlying chronic liver diseases. 
 
8.2 Aim 2: Platelet GPIbα is a mediator and potential interventional target for 
NASH and subsequent liver cancer 
Adapted from my written and experimental contribution in Malehmir*, Pfister* et al.9: Further, 
in the frame of this PhD thesis, I report several findings that help to target or intervene with 
hepatic inflammation in NASH in an alternative way, without targeting potentially inflammation-
driving immune cell populations like the hepatic PD-1+TNF-a+ CD8+ T-cells described above. 
Platelets have been identified as a crucial factor mediating cytotoxic T-cell responses in virus-
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induced liver inflammation, highlighting a potential direct interaction of platelet-CD8+ T-cells in 
NASH development, NASH progression and NASH-induced hepatocarcinogenesis64–66. 
My data indicated that increased hepatic platelet numbers and aggregates and enhanced 
platelet activation are distinct features not of long-term HFD feeding-inducing NAFLD, but of 
long-term feeding of NASH-inducing diets like CD-HFD and WD-HTF. This finding was 
corroborated in mice with using different western-style diets (WD-non trans fats, or WD with 
fructose-supplemented drinking water), MCD, genetic models (hURI-tetOFF combined with 
HFD) but also in human patients9. Further, my data indicated that platelets in NASH diseased 
mice are activated and that manipulation of this platelet activation using Ticagrelor as APT is 
ameliorating or abrogating the progression of NASH pathology. Interestingly, fibrosis, which is 
detrimental for HCC induction, was also reduced upon therapeutic APT using the reversible 
P2Y12 antagonists Ticagrelor9. Other groups using virus-associated hepatitis models report 
beneficial effects (e.g. prolonged survival) of APT, as well67. 
To understand the dynamics of intrahepatic platelet recruitment and attachment during the 
initial events of NASH development, I in collaboration with Moritz Peiseler, Bas Surewaard and 
Paul Kubes showed that platelets indeed home to the liver at the earliest time points of 
borderline NASH development9. Potential mechanisms could be increased physical and 
therefore potential receptor ligand interaction of platelets with other cell types in the blood flow. 
In collaboration with Suchira Gallage I showed an increase of hepatocyte size, decreased 
sinusoidal diameter and thus a potential local increase of blood flow pressure, potentially 
leading to a local environment of blood flow similar to arterial thrombosis in the background of 
atherosclerotic plaques123. However, my data indicated that there are specific platelet-KC 
interactions that lead to platelet attachment, recruitment and abundance in early phases of 
NASH development, as well as in NASH progression9. Further, my data indicated that there 
are specific platelet-CD44-hyaluronan-dependent mechanisms that lead to platelet attachment 
and recruitment in early phases NASH development9. Guidotti et al. reported similar findings 
on the importance of the CD44-hyaluronan axis for platelet adherence to the sinusoids in order 
to mediate docking of circulating CD8+ T-cells in a model of HBV66. Although granulocytes are 
reported as being a cell type that homes to damaged tissue, mediating early inflammation78, 
as well as interacting with the CD44-hyaluronan axis124, I in collaboration with Caroline L. 
Wilson, Jack Leslie and Derek A. Mann could not observe significant effects on NASH 
development and NASH progression after 2 months of granulocyte depletion. Thus, 
granulocytes may play a minor role in the CD-HFD NASH mouse model. Thus, my data shed 
new light on intrahepatic platelet recruitment and attachment during the initial events of NASH 
development.  
However, patients with established NASH with the risk of hepatocarcinogenesis are seen in 
the clinics; therefore, there is a great demand for targeting platelets with alternative strategies 
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besides APT, for example, with new druggable targets, which allow modifying platelet functions 
in a specific manner. Based on previous work59, I could strengthen the hypothesis that GPIbα 
on platelets is important for platelet attachment, as well as platelet activation in NASH 
development, potentially in a platelet-KC-dependent manner. Langer et al. described a similar 
inflammation-promoting role of GPIbα in experimental autoimmune encephalomyelitis (EAE), 
in which platelet-derived, GPIbα mediated recruitment of immune cells to the inflamed central 
nervous system9,125. My data indicated in a genetic model that dysfunctional GPIbα correlated 
with NASH prevention59 and therefore the livers lacked the pro-carcinogenic NASH-related 
environment in hIL4rα/GP1bα-Tg mice59, which subsequently led to abrogated NASH-induced 
hepatocarcinogenesis9. Further, I could show, that therapeutic Fab-mediated blocking of 
GPIbα ameliorates NASH pathology and dampening fibrosis, highlighting the translational role 
of GPIbα as a potential interventional druggable target in NASH9,59,60. Of note, for clinical 
applications one has to consider that although the GPIbα receptor is left intact, interfering with 
platelet activation by antibody-mediated GPIbα blocking induces prolonged bleeding times in 
mice, but no spontaneous bleeding9,126. In conclusion, due to the lack of effective and safe 
treatment options targeting NASH specifically (e.g. Insulin-sensitizer pioglitazone, obeticholic 
acid or vitamin E), antibody-mediated GPIbα blocking could be a potentially safe new treatment 
against a metabolic disease like NASH, potentially in a combinatorial approach with additional 
anti-inflammatory or anti-fibrotic drugs9,127,128. 
As a result, my data presented in aim 2 (“Platelet GPIbα is a mediator and potential 
interventional target for NASH and subsequent liver cancer”) in the frame of this PhD thesis 
contributed significantly to a Nature Medicine publication, in which the role of APTs, KCs, 
platelet-related mechanisms and potential ligands of GPIbα (P-selectin, VWF and Mac-1) are 
investigated9. 
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